Multispecific molecule targeting il-11 and TSLP for treating diseases
By designing multispecific antibodies and antigen-binding fragments targeting IL-11 and TSLP, the problem of targeting difficulties in existing technologies has been solved, achieving highly efficient treatment of inflammatory and fibrotic diseases, simplifying the preparation process and improving stability.
Patent Information
- Application Number
- PCT/CN2026/096096
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-19
AI Technical Summary
Existing technologies are unable to effectively target IL-11 and TSLP, which poses challenges to the development of drugs for treating inflammatory and fibrotic diseases, such as low expression levels, poor stability, complex processes, and large differences in quality control.
Develop an antibody and/or antigen-binding fragment containing a first binding domain targeting IL-11 and a second binding domain targeting TSLP, using specific amino acid sequences and linkages to form a multispecific molecule for the treatment of related diseases.
It achieves highly efficient targeting of IL-11 and TSLP, improves the efficacy of treating inflammatory and fibrotic diseases, simplifies the preparation process, and enhances stability and consistency.
Smart Images

Figure PCTCN2026096096-FTAPPB-I100001 
Figure PCTCN2026096096-FTAPPB-I100002 
Figure PCTCN2026096096-FTAPPB-I100003
Abstract
Description
Multispecific molecular therapy targeting IL-11 and TSLP for diseases Technical Field
[0001] This invention relates to the field of biomedicine, specifically to the use of an antibody and / or antigen-binding fragment targeting IL-11 and TSLP in the treatment of inflammatory and / or fibrotic diseases. Background Technology
[0002] Thymic stromal lymphopoietin (TSLP) is an interleukin-7 (IL-7) cytokine. Mature hTSLP consists of 131 amino acid residues and exhibits a typical four-strand α-helix bundle structure. It is mainly produced in epithelial cells, smooth muscle cells, keratinocytes, stromal cells, fibroblasts, mast cells (MCs), monocytes / macrophages, granulocytes, and dendritic cells (DCs). As an important allergic factor secreted by epithelial cells, TSLP induces the Th2 response through its interaction with locally infiltrating DCs and T cells. Furthermore, TSLP can inhibit the Th1 pathway, shifting the inflammatory response from Th1 to Th2, thus playing a crucial coordinating and balancing role in the inflammatory response.
[0003] Interleukin-11 (IL-11), discovered in 1990, is a member of the IL-6 family, containing 178 amino acids with a molecular weight of approximately 19 kDa. IL-11 is expressed in various cell types, including leukocytes, fibroblasts, and epithelial cells; its expression is regulated by various cytokines, such as TGF-β, IL-1β, IL-22, IL-17F, IFN-γ, TNF-α, and COX-2. IL-11 activates downstream signaling pathways by binding to the α subunit of the IL-11 receptor (IL-11Rα), which in turn forms a 2:2:2 (IL-11 / IL-11Rα / GP130) complex with the β subunit of the glycoprotein receptor (GP130).
[0004] Fibrotic diseases are a group of serious threats to human health, characterized by the abnormal deposition of extracellular matrix within organs or tissues, leading to organ structural damage and functional decline. They commonly occur in multiple organs, including the lungs, liver, kidneys, heart, and skin, such as idiopathic pulmonary fibrosis, liver fibrosis, renal interstitial fibrosis, myocardial fibrosis, and systemic sclerosis. These diseases often progress slowly but can eventually lead to organ failure and even death, and currently, there are no effective treatments.
[0005] TSLP and IL-11 share a common mechanism in inflammation and fibrosis. Studies have found that TSLP can promote fibrosis during tissue repair. If the fibrosis stage continues to progress unchecked, the result of fibrotic disease can be extensive tissue remodeling and the formation of permanent scar tissue.
[0006] In clinical applications, IL-11 is highly expressed in diseases such as asthma, atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF), and its expression level is closely related to the severity of the disease.
[0007] While developing drugs targeting IL-11 and TSLP is of great significance, it also faces numerous challenges, such as preclinical evaluation models, low expression levels, poor stability, complex manufacturing processes, and significant variability in quality control. Therefore, there is an urgent need in this field to develop a multispecific molecule that is highly specific, effective, and easy to prepare, in order to better treat related diseases. Summary of the Invention
[0008] On one hand, the present invention provides the use of an antibody and / or antigen-binding fragment in the treatment of inflammation and / or fibrosis, said antibody and / or antigen-binding fragment comprising a first binding domain capable of targeting IL-11 and a second binding domain capable of targeting TSLP.
[0009] In some embodiments, the first binding domain in the antibody and / or antigen-binding fragment capable of targeting IL-11 includes HCDR1, HCDR2, and HCDR3 of VH as shown in SEQ ID NO: 4.
[0010] In some embodiments, the first binding domain capable of targeting IL-11 comprises HCDR3, HCDR2, and HCDR1 of the heavy chain variable region VH; wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO:1, the amino acid sequence of HCDR2 is shown in SEQ ID NO:2, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:3.
[0011] In some embodiments, the first binding domain capable of targeting IL-11 comprises the antibody heavy chain variable region VH, and the VH comprises the amino acid sequence shown in SEQ ID NO:4.
[0012] In some implementations, the first binding domain capable of targeting IL-11 is VHH.
[0013] In some embodiments, the VHH comprises the amino acid sequence shown in SEQ ID NO:4 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% compared to it.
[0014] In some embodiments, the antigen-binding fragment is selected from the group consisting of: Fab, Fab', F(ab)2, Fv fragment, F(ab')2, scFv, di-scFv, VHH, and dAb fragment.
[0015] In some embodiments, the antibody and / or antigen-binding fragment capable of targeting the second TSLP binding domain includes HCDR1, HCDR2, and HCDR3 of VH as shown in SEQ ID NO: 14.
[0016] In some embodiments, the antibody and / or antigen-binding fragment capable of targeting the second binding domain of TSLP includes LCDR1, LCDR2, and LCDR3 of VL as shown in SEQ ID NO: 15.
[0017] In some embodiments, the second binding domain capable of targeting TSLP comprises HCDR1, HCDR2, and HCDR3 of the heavy chain variable region VH; wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO:8, the amino acid sequence of HCDR2 is shown in SEQ ID NO:9, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:10.
[0018] In some embodiments, the second binding domain capable of targeting TSLP comprises LCDR1, LCDR2, and LCDR3 of the light chain variable region VL; wherein the amino acid sequence of LCDR1 is shown in SEQ ID NO:11, the amino acid sequence of LCDR2 is shown in SEQ ID NO:12, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:13.
[0019] In some embodiments, the second binding domain capable of targeting TSLP comprises an antibody heavy chain variable region VH as shown in SEQ ID NO:14 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to it.
[0020] In some embodiments, the second binding domain capable of targeting TSLP comprises an antibody light chain variable region VL as shown in SEQ ID NO:15 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to it.
[0021] In some embodiments, the second binding domain capable of targeting TSLP comprises a combination of VH and VL as shown in SEQ ID NO:14 and 15 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to them.
[0022] In some embodiments, the second binding domain capable of targeting TSLP includes the antibody heavy chain constant region.
[0023] In some embodiments, the antibody heavy chain constant region is derived from the human IgG heavy chain constant region.
[0024] In some embodiments, the second binding domain capable of targeting TSLP includes a constant region of the antibody light chain.
[0025] In some embodiments, the antibody light chain constant region is derived from the human Igκ constant region.
[0026] In some embodiments, the second binding domain capable of targeting TSLP comprises an antibody heavy chain comprising an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identical to that shown in SEQ ID NO:6.
[0027] In some embodiments, the second binding domain capable of targeting TSLP comprises an antibody light chain comprising an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identical to that shown in SEQ ID NO:7.
[0028] In some implementations, the first binding domain capable of targeting IL-11 and the second binding domain capable of targeting TSLP are directly or indirectly connected.
[0029] In some implementations, the C-terminus of the first binding domain capable of targeting IL-11 is connected to the N-terminus of the second binding domain capable of targeting TSLP.
[0030] In some embodiments, the C-terminus of the first binding domain capable of targeting IL-11 is connected to the N-terminus of the heavy chain variable region VH of the second binding domain targeting TSLP.
[0031] In some implementations, the N-terminus of the first binding domain capable of targeting IL-11 is connected to the C-terminus of the second binding domain capable of targeting TSLP.
[0032] In some embodiments, the N-terminus of the first binding domain capable of targeting IL-11 is connected to the C-terminus of the heavy chain constant region of the second binding domain targeting TSLP.
[0033] In some implementations, the first binding domain capable of targeting IL-11 is connected to the second binding domain targeting TSLP via a connector.
[0034] In some embodiments, the linker comprises a peptide linker.
[0035] In some embodiments, the linker comprises an amino acid sequence of (GGGGS)n, where n is any positive integer from 0 to 10.
[0036] In some embodiments, the linker comprises the amino acid sequence shown in GGGGSGGGGS (SEQ ID NO:5).
[0037] In some embodiments, the multispecific molecule comprises two first binding domains capable of targeting IL-11.
[0038] In some embodiments, the two first binding domains capable of targeting IL-11 are directly or indirectly connected to the N-terminus of the two heavy chains of the second binding domain targeting TSLP.
[0039] In some embodiments, the two first binding domains capable of targeting IL-11 are directly or indirectly connected to the C-terminus of the two heavy chains of the second binding domain targeting TSLP.
[0040] In some embodiments, the multispecific molecule comprises a first polypeptide chain and a second polypeptide chain.
[0041] In some embodiments, the first polypeptide chain comprises a heavy chain that can target a first binding domain of IL-11 and a second binding domain of TSLP.
[0042] In some embodiments, the first polypeptide chain includes the N-terminus of the heavy chain containing the first binding domain capable of targeting IL-11 and the second binding domain capable of targeting TSLP, which are directly or indirectly linked.
[0043] In some embodiments, the first polypeptide chain includes the C-terminus of the heavy chain containing the first binding domain capable of targeting IL-11 and the second binding domain capable of targeting TSLP, which are directly or indirectly linked.
[0044] In some embodiments, the first polypeptide chain includes a heavy chain comprising a first binding domain capable of targeting IL-11 and a second binding domain capable of targeting TSLP, linked by a linker.
[0045] In some embodiments, the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO:18.
[0046] In some embodiments, the second polypeptide chain comprises a light chain of the second binding domain.
[0047] In some embodiments, the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO:19.
[0048] In some embodiments, the multispecific molecule comprises two of the first polypeptide chains and two of the second polypeptide chains.
[0049] In some embodiments, the first polypeptide chain and the second polypeptide chain are linked by disulfide bonds.
[0050] In some implementations, the inflammatory disease includes type 2 inflammatory disease.
[0051] In some embodiments, the inflammatory disease may be a Th2 cell-related disease.
[0052] In some implementations, the inflammatory disease may be asthma, atopic dermatitis, etc.
[0053] In some embodiments, the fibrosis is fibrosis of the heart, liver, kidneys, lungs, skin, or eyes.
[0054] In some implementations, the fibrosis is present in the lungs.
[0055] In some embodiments, the fibrosis is pulmonary fibrosis.
[0056] In some embodiments, the pulmonary fibrosis may be asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, etc.
[0057] In some implementations, the fibrosis is present in the kidneys.
[0058] In some embodiments, the fibrosis is renal fibrosis.
[0059] In some embodiments, the fibrosis is present in the skin.
[0060] In some embodiments, the skin fibrosis may be atopic dermatitis, etc.
[0061] On the other hand, the present invention provides the use of a pharmaceutical combination comprising a first antibody capable of targeting IL-11 and a second antibody targeting TSLP in the treatment of inflammation and / or fibrosis.
[0062] In some embodiments, the first antibody and the second antibody are present in the form of a mixture.
[0063] In some implementations, the first antibody and the second antibody exist independently.
[0064] In some embodiments, the antibody is selected from the group consisting of monoclonal antibodies, single-chain antibodies, chimeric antibodies, nanobodies, multispecific antibodies, humanized antibodies, and fully human antibodies.
[0065] In some embodiments, the first antibody comprises HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO: 4.
[0066] In some embodiments, the first antibody comprises HCDR3, HCDR2 and HCDR1 of the heavy chain variable region VH; wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO:1, the amino acid sequence of HCDR2 is shown in SEQ ID NO:2 and the amino acid sequence of HCDR3 is shown in SEQ ID NO:3.
[0067] In some embodiments, the first antibody comprises a variable region VH of the antibody heavy chain, and the amino acid sequence of the VH is shown in SEQ ID NO:4.
[0068] In some embodiments, the first antibody is a nanobody comprising and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the amino acid sequence shown in SEQ ID NO:4 and / or compared to it.
[0069] In some embodiments, the second antibody comprises HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO: 14.
[0070] In some embodiments, the second antibody comprises LCDR1, LCDR2 and LCDR3 of VL as shown in SEQ ID NO: 15.
[0071] In some embodiments, the second antibody comprises HCDR1, HCDR2 and HCDR3 of the heavy chain variable region VH; wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO:8, the amino acid sequence of HCDR2 is shown in SEQ ID NO:9 and the amino acid sequence of HCDR3 is shown in SEQ ID NO:10.
[0072] In some embodiments, the second antibody comprises LCDR1, LCDR2, and LCDR3 of the light chain variable region VL; wherein the amino acid sequence of LCDR1 is shown in SEQ ID NO:11, the amino acid sequence of LCDR2 is shown in SEQ ID NO:12, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:13.
[0073] In some embodiments, the second antibody comprises an antibody heavy chain variable region VH as shown in SEQ ID NO:14 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to it.
[0074] In some embodiments, the second antibody comprises an antibody light chain variable region VL as shown in SEQ ID NO:15 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to it.
[0075] In some embodiments, the second antibody comprises a combination of VH and VL as shown in SEQ ID NO:14 and 15 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to them.
[0076] In some embodiments, the second antibody comprises an antibody heavy chain that comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with respect to SEQ ID NO:6.
[0077] In some embodiments, the second antibody comprises an antibody light chain comprising an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identical to that shown in SEQ ID NO:7.
[0078] In some implementations, the inflammatory disease includes type 2 inflammatory disease.
[0079] In some embodiments, the inflammatory disease may be a Th2 cell-related disease.
[0080] In some implementations, the inflammatory disease may be asthma, atopic dermatitis, etc.
[0081] In some embodiments, the fibrosis is fibrosis of the heart, liver, kidneys, lungs, skin, or eyes.
[0082] In some implementations, the fibrosis is present in the lungs.
[0083] In some embodiments, the fibrosis is pulmonary fibrosis.
[0084] In some embodiments, the pulmonary fibrosis may be asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, etc.
[0085] In some implementations, the fibrosis is present in the kidneys.
[0086] In some embodiments, the fibrosis is renal fibrosis.
[0087] In some embodiments, the fibrosis is present in the skin.
[0088] In some embodiments, the skin fibrosis may be atopic dermatitis, etc.
[0089] On the other hand, the present invention also provides the use of one or more nucleic acid molecules encoding the aforementioned antibody and / or antigen-binding fragments in the treatment of inflammation and / or fibrosis.
[0090] On the other hand, the present invention also provides the use of a carrier containing the aforementioned nucleic acid molecules in the treatment of inflammation and / or fibrosis.
[0091] On the other hand, the present invention also provides the use of cells comprising the said nucleic acid molecules or the said carrier in the treatment of inflammation and / or fibrosis.
[0092] On the other hand, the present invention also provides the use of chimeric antigen receptors comprising the antibodies and / or antigen-binding fragments described herein in the treatment of inflammation and / or fibrosis.
[0093] On the other hand, the present invention also provides the use of immune conjugates comprising the antibodies and / or antigen-binding fragments described herein in the treatment of inflammation and / or fibrosis.
[0094] On the other hand, the present invention also provides the antibody and / or antigen-binding fragment, the chimeric antigen receptor, the polypeptide molecule, the nucleic acid molecule, the carrier, the cell, the immune conjugate and / or the drug combination for the prevention, relief and / or treatment of inflammatory and / or fibrotic diseases and / or conditions.
[0095] In some implementations, the inflammatory disease includes type 2 inflammatory disease.
[0096] In some embodiments, the inflammatory disease may be a Th2 cell-related disease.
[0097] In some implementations, the inflammatory disease may be asthma, atopic dermatitis, etc.
[0098] In some embodiments, the fibrosis is fibrosis of the heart, liver, kidneys, lungs, skin, or eyes.
[0099] In some implementations, the fibrosis is present in the lungs.
[0100] In some embodiments, the fibrosis is pulmonary fibrosis.
[0101] In some embodiments, the pulmonary fibrosis may be asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, etc.
[0102] In some implementations, the fibrosis is present in the kidneys.
[0103] In some embodiments, the fibrosis is renal fibrosis.
[0104] In some embodiments, the fibrosis is present in the skin.
[0105] In some embodiments, the fibrosis may be atopic dermatitis, etc.
[0106] On the other hand, the present invention also provides the use of the antibody and / or antigen-binding fragment, the chimeric antigen receptor, the polypeptide molecule, the nucleic acid molecule, the carrier, the cell, the immunoconjugate and / or the drug combination in the preparation of a medicament for the prevention, relief and / or treatment of inflammatory and / or fibrotic diseases and / or conditions.
[0107] In some implementations, the inflammatory disease includes type 2 inflammatory disease.
[0108] In some embodiments, the inflammatory disease may be a Th2 cell-related disease.
[0109] In some implementations, the inflammatory disease may be asthma, atopic dermatitis, etc.
[0110] In some embodiments, the fibrosis is fibrosis of the heart, liver, kidneys, lungs, skin, or eyes.
[0111] In some implementations, the fibrosis is present in the lungs.
[0112] In some embodiments, the fibrosis is pulmonary fibrosis.
[0113] In some embodiments, the pulmonary fibrosis may be asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, etc.
[0114] In some implementations, the fibrosis is present in the kidneys.
[0115] In some embodiments, the fibrosis is renal fibrosis.
[0116] In some embodiments, the fibrosis is present in the skin.
[0117] In some embodiments, the skin fibrosis may be atopic dermatitis, etc.
[0118] On the other hand, the present invention also provides the antibody and / or antigen-binding fragment, the chimeric antigen receptor, the polypeptide molecule, the nucleic acid molecule, the carrier, the cell, and / or the drug combination for the prevention and / or treatment of inflammatory and / or fibrotic diseases and / or conditions.
[0119] In some implementations, the inflammatory disease includes type 2 inflammatory disease.
[0120] In some embodiments, the inflammatory disease may be a Th2 cell-related disease.
[0121] In some implementations, the inflammatory disease may be asthma, atopic dermatitis, etc.
[0122] In some embodiments, the fibrosis is fibrosis of the heart, liver, kidneys, lungs, skin, or eyes.
[0123] In some implementations, the fibrosis is present in the lungs.
[0124] In some embodiments, the fibrosis is pulmonary fibrosis.
[0125] In some embodiments, the pulmonary fibrosis may be asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, etc.
[0126] In some implementations, the fibrosis is present in the kidneys.
[0127] In some embodiments, the fibrosis is renal fibrosis.
[0128] In some embodiments, the fibrosis is present in the skin.
[0129] In some embodiments, the skin fibrosis may be atopic dermatitis, etc.
[0130] Other aspects and advantages of the invention will be readily apparent to those skilled in the art from the following detailed description. Only exemplary embodiments of the invention are shown and described in the following detailed description. As will be appreciated by those skilled in the art, the content of this invention enables them to make modifications to the disclosed specific embodiments without departing from the spirit and scope of the invention. Accordingly, the descriptions in the accompanying drawings and specification are merely exemplary and not restrictive. Attached Figure Description
[0131] Figure 1 shows the structure of antibody I700021 of the present invention.
[0132] Figure 2 shows the immunofluorescence detection results of TGF-beta-induced fibrosis inhibited by the antibody of the present invention.
[0133] Figure 3. Flow cytometry results of the antibody of this invention inhibiting TGF-beta-induced fibrosis.
[0134] Figure 4 shows the ELISA detection results of the antibody of the present invention inhibiting IL-11-induced ERK1 / 2 phosphorylation.
[0135] Figure 5. Flow cytometry results of the antibody of this invention blocking IL-11-induced IL-33 activity.
[0136] Figure 6 shows the results of BALF eosinophil detection in a mouse model of pulmonary fibrosis treated with the antibody of this invention.
[0137] Figure 7 shows the results of Fibronectin content detection in lung tissue of a mouse model of pulmonary fibrosis treated with the antibody of the present invention.
[0138] Figure 8. Masson staining image of the lungs in a mouse model of pulmonary fibrosis treated with the antibody of this invention.
[0139] Figure 9. Quantitative detection results of glomerular fibrosis by PAS staining in the UUO mouse model treated with the antibody of this invention.
[0140] Figure 10. Quantitative detection results of renal tubular fibrosis by Masson staining in the UUO mouse model treated with the antibody of this invention.
[0141] Figure 11 shows the results of skin IL-4 content detection in the atopic dermatitis model treated with the antibody of this invention.
[0142] Figure 12 shows the results of eosinophil count detection in the atopic dermatitis model treated with the antibody of this invention. Detailed Implementation
[0143] Terminology Definition
[0144] In this invention, the term "IL-11" generally refers to a stromal cell-derived cytokine belonging to the IL-6 superfamily. The term "IL-11" encompasses "full-length," unprocessed IL-11, and any form of IL-11 produced by cellular processing. In this invention, the term "IL-11" includes its mutants, fragments, variants, isotypes, and homologs.
[0145] In this invention, the term "TSLP," also known as "thymic stromal lymphopoietin," is an interleukin-7 (IL-7) cytokine. Mature hTSLP consists of 131 amino acid residues and exhibits a typical four-strand α-helix bundle structure. The term "TSLP" encompasses "full-length," unprocessed TSLP, and any form of TSLP produced by cellular processing. In this invention, the term "TSLP" includes full-length wild-type TSLP and its mutants, fragments, variants, isotypes, and homologs.
[0146] In this invention, the term "isolated" generally refers to something obtained artificially from its natural state. If a substance or component is found in nature as an "isolated" substance, it may be due to an alteration of its natural environment, the isolation of the substance from its natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide may naturally exist in the body of a living animal, and a high-purity identical polynucleotide or polypeptide isolated from this natural state is called isolated. The term "isolated" does not exclude the presence of artificial or synthetic substances, nor does it exclude the presence of other impurities that do not affect the activity of the substance.
[0147] In this invention, the term "isolated antigen-binding protein" generally refers to a protein with antigen-binding ability obtained artificially from its natural state. This "isolated antigen-binding protein" may include a portion that binds to an antigen, and optionally, the antigen-binding portion may employ a framework or structural portion that promotes the conformation of the antigen-binding portion to bind to the antigen. The antigen-binding protein may include, for example, an antibody-derived protein framework region (FR) or an alternative protein framework region or artificial framework region having a transplanted CDR or CDR derivative. Such frameworks include, but are not limited to, antibody-derived framework regions containing mutations introduced, for example, to stabilize the three-dimensional structure of the antigen-binding protein, and fully synthetic framework regions containing, for example, biocompatible polymers. Examples of antigen-binding proteins include, but are not limited to: human antibodies, humanized antibodies; chimeric antibodies; recombinant antibodies; single-chain antibodies; bifunctional antibodies; trifunctional antibodies; tetrafunctional antibodies; Fab, Fab', Fv fragments, F(ab')2, F(ab)2, scFv, di-scFv, dAb, IgD antibodies; IgE antibodies; IgM antibodies; IgG1 antibodies; IgG2 antibodies; IgG3 antibodies; or IgG4 antibodies and fragments thereof.
[0148] In this invention, the term "antibody" (Ab) refers to an immunoglobulin molecule that specifically binds to or is immunoreactive with a target antigen, including polyclonal, monoclonal, genetically engineered, and other modified forms of antibodies (including, but not limited to, chimeric antibodies, humanized antibodies, fully human antibodies, heterologous conjugates (e.g., bispecific, trispecific, and tetraspecific antibodies, biantibodies, triantibodies, and tetraantibodies, antibody conjugates) and antigen-binding fragments of antibodies (including, for example, Fab', F(ab')2, Fab, Fv, rIgG, and scFv fragments). Furthermore, unless otherwise stated, the term "monoclonal antibody" (mAb) means both complete antibody molecules capable of specifically binding to a target protein and incomplete antibody fragments (e.g., Fab and F(ab')2 fragments, which lack the Fc fragment of the complete antibody (which is cleared more quickly from animal circulation) and therefore lack Fc-mediated effector function (see Wahl et al., J. Nucl. Med. 24:316, 1983; the contents of which are incorporated herein by reference).
[0149] In this invention, the term "antibody" can be derived from any animal, including but not limited to humans and non-human animals. The non-human animals can be selected from primates, mammals, rodents and vertebrates, such as camels, llamas, ostriches, alpacas, sheep, rabbits, mice, rats or cartilaginous fish (e.g., sharks).
[0150] In this invention, the term "antigen-binding fragment" refers to one or more antibody fragments that retain the ability to specifically bind to a target antigen. The antigen-binding function of an antibody can be performed by a fragment of a full-length antibody. The antibody fragment can be Fab, F(ab')2, scFv, biantibody, triantibody, affibody, nanobody, aptamer, or domain antibody. Examples of binding fragments encompassing the term "antigen-binding fragment" for antibody include, but are not limited to: (i) Fab fragments, a monovalent fragment consisting of VL, VH, CL, and CH1 domains; (ii) F(ab)2 fragments, a bivalent fragment comprising two Fab fragments linked by disulfide bonds in a hinge region; (iii) Fd fragments consisting of VH and CH1 domains; (iv) Fv fragments consisting of VL and VH domains of an antibody arm; (v) dAbs containing VH and VL domains; (vi) dAb fragments consisting of VH domains (Ward et al., Nature 341:544-546, 1989; the contents of which are incorporated herein by reference); (vii) dAbs consisting of either VH or VL domains; (viii) separate complementarity-determining regions (CDRs); and (ix) combinations of two or more separate CDRs, which may optionally be linked by synthetic linkers. Furthermore, although the two domains VL and VH of the Fv fragment are encoded by independent genes, these two domains can be joined using recombination methods via a linker that enables the creation of a single protein chain in which the VL and VH regions pair to form a monovalent molecule (referred to as a single-chain Fv (scFv); see, for example, Bird et al., Science 242:423-426, 1988 and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988; the contents of which are incorporated herein by reference). These antibody fragments can be obtained using conventional techniques known to those skilled in the art, and these fragments are screened for use in the same manner as intact antibodies. Antigen-binding fragments can be generated by recombinant DNA techniques, enzymatic or chemical cleavage of intact immunoglobulins, or, in some embodiments, by chemical peptide synthesis procedures known in the art.
[0151] In this invention, the term "specific binding" refers to a binding reaction that determines the presence of an antigen within a heterogeneous population of proteins and other biomolecules, such as those specifically recognized by an antibody or its antigen-binding fragment. Antibodies or their antigen-binding fragments that specifically bind to an antigen will bind with a KD less than 100 nM. For example, antibodies or their antigen-binding fragments that specifically bind to an antigen will bind with a KD up to 100 nM (e.g., between 1 pM and 100 nM). Antibodies or their antigen-binding fragments that do not show specific binding to a particular antigen or its epitope will show a KD greater than 100 nM (e.g., greater than 500 nM, 1 μM, 100 μM, 500 μM, or 1 mM) for that particular antigen or its epitope. Various immunoassays can be used to select antibodies that specifically react with a particular protein or carbohydrate. For example, solid-phase ELISA is conventionally used to select antibodies that specifically react with a protein or carbohydrate. See Harlow & Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1988) and Harlow & Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1999), which describe the immunoassays and conditions that can be used to determine specific immune reactivity (which are incorporated herein by reference).
[0152] In this invention, the term "monospecific" refers to having one or more binding sites, wherein each binding site binds the same epitope of the same antigen.
[0153] In this invention, the term "multispecific" refers to having at least two antigen-binding sites, each of which binds to a different epitope of the same antigen or to a different epitope of a different antigen. Therefore, terms such as "bispecific," "trispecific," and "quadrispecific" refer to the number of different epitopes that an antibody / antigen binding molecule can bind to.
[0154] In this invention, the term "multispecific molecule" generally refers to an antibody having a variable region that recognizes one or more epitopes on one or more antigens. Multispecific antibodies include, but are not limited to, full-length antibodies, antibodies having two or more VL and VH domains (such as monoclonal antibodies, chimeric antibodies, humanized antibodies, and fully human antibodies), antibody fragments (such as Fab, Fab', F(ab)2, Fv fragments, F(ab')2, scFv, di-scFv, VHH, and dAb), biantibodies, bispecific biantibodies, and triantibodies, and antibody fragments that are covalently or non-covalently linked. In some embodiments, a multispecific antibody may be a "bispecific antibody" that recognizes two different epitopes on the same or different antigens.
[0155] In this invention, the terms "full-length antibody," "intact antibody," and "complete antibody" are used interchangeably, referring to antibodies that have a structure substantially similar to that of natural antibodies.
[0156] In this invention, the term "CDR," also known as "complementarity-determining region," typically refers to a region within the variable structural domain of an antibody whose sequence is highly variable and / or forms a structurally defining loop. Typically, an antibody comprises six CDRs: three in the VH (HCDR1, HCDR2, HCDR3) and three in the VL (LCDR1, LCDR2, LCDR3). In some embodiments, naturally occurring camel antibodies consisting only of heavy chains can function normally and stably even in the absence of light chains. Antibody CDRs can be determined using various coding systems, such as CCG, Kabat, Chothia, IMGT, and a combination of Kabat / Chothia. These coding systems are known in the art. For example, the CDRs of a multispecific molecule can be classified according to the IMGT numbering system. For example, the CDRs of a multispecific molecule can be classified according to the Kabat numbering system. For example, the CDRs of a multispecific molecule can be classified according to the Chothia numbering system. For example, the CDR of the multispecific molecule that targets the first binding domain of IL-11 / antibody can be classified according to the Kabat numbering system. For example, among the multispecific molecules, the CDRs that can target the second binding domain / antibody of TSLP can be classified according to the IMGT numbering system.
[0157] In this invention, the term "FR" generally refers to a more conserved portion of the antibody variable domain, which is called the frame region. Typically, the variable domains of the natural heavy and light chains each contain four FR regions, namely four in VH (H-FR1, H-FR2, H-FR3, and H-FR4) and four in VL (L-FR1, L-FR2, L-FR3, and L-FR4).
[0158] In this invention, the terms "variable domain" and "variable region" are used interchangeably and generally refer to a portion of the antibody heavy chain and / or light chain. The variable domains of the heavy and light chains may be referred to as "VH" and "VL" (or "VH" and "VL" respectively). These domains are typically the most variable parts of the antibody (relative to other antibodies of the same type) and contain antigen-binding sites.
[0159] In this invention, the term "VHH" generally refers to an antibody containing a variable antigen-binding domain of a heavy chain antibody. VHH may also be referred to as a nanobody (Nb), a heavy chain antibody, and / or a single-domain antibody. For example, the VHH may bind to IL-11. For example, the VHH may be specific for IL-11.
[0160] In this invention, the term "heavy chain constant region" refers to the carboxyl-terminal portion of the antibody heavy chain, which does not directly participate in the binding of the antibody to the antigen but exhibits effector functions, such as interaction with the Fc receptor, and has a more conserved amino acid sequence relative to the variable domains of the antibody. The "heavy chain constant region" comprises at least one of the following: a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, or a variant or fragment thereof. The "heavy chain constant region" includes a "full-length heavy chain constant region" and a "heavy chain constant region fragment," the former having a structure substantially similar to the natural antibody constant region, while the latter comprises only a portion of the full-length heavy chain constant region. Exemplarily, a typical "full-length antibody heavy chain constant region" consists of a CH1 domain-hinge region-CH2 domain-CH3 domain; when the antibody is IgE, it also includes a CH4 domain; when the antibody is a heavy chain antibody, it does not include the CH1 domain. Exemplarily, a typical "heavy chain constant region fragment" may be selected from the CH1, Fc, or CH3 domains.
[0161] In this invention, the term "light chain constant region" refers to the carboxyl terminus of the antibody light chain, which does not directly participate in the binding of the antibody to the antigen. The light chain constant region can be selected from a constant κ domain or a constant λ domain.
[0162] In this invention, the term "Fc" refers to the carboxyl-terminal portion of an antibody obtained by papain hydrolysis of an intact antibody, typically comprising the CH3 and CH2 domains of the antibody. The Fc region includes, for example, the native sequence Fc region, the recombinant Fc region, and the variant Fc region. Although the boundaries of the Fc region of the immunoglobulin heavy chain can vary slightly, the Fc region of the human IgG heavy chain is generally defined as extending from the amino acid residue at Cys226 or from Pro230 to its carboxyl terminus. The C-terminal lysine of the Fc region (residue 447 according to the EU numbering system) can be removed, for example, during antibody production or purification, or by recombinant engineering of the nucleic acid encoding the antibody heavy chain; therefore, the Fc region may or may not include Lys447.
[0163] In this invention, the term "humanized antibody" refers to a genetically engineered non-human antibody whose amino acid sequence is modified to increase homology with that of a human antibody. Typically, all or part of the CDR region of a humanized antibody is derived from a non-human antibody (donor antibody), and all or part of the non-CDR region (e.g., the variable region FR and / or constant region) is derived from a human immunoglobulin (receptor antibody). Humanized antibodies generally retain or partially retain the intended properties of the donor antibody, including but not limited to antigen specificity, affinity, reactivity, ability to enhance immune cell activity, and ability to enhance immune responses.
[0164] In this invention, the term "fully human antibody" refers to an antibody having variable regions in which both the FR and CDR are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, that constant region is also derived from a human germline immunoglobulin sequence. Fully human antibodies described herein may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced through random or site-specific mutagenesis in vitro or through somatic mutations in vivo). However, "fully human antibody" herein is not intended to include antibodies in which a CDR sequence derived from another mammalian species (e.g., mouse) has been grafted onto a human frame sequence.
[0165] In this invention, the term "naked antibody" refers to an antibody that is not linked, fused, or conjugated to another agent or molecule (e.g., a label or drug), peptide, or polypeptide. In specific embodiments, naked antibodies expressed by mammalian host cells can be glycosylated by the host cell's glycosylation machinery (e.g., glycosylation enzymes). In some embodiments, naked antibodies are not glycosylated when expressed by host cells that do not possess their own glycosylation machinery (e.g., glycosylation enzymes). In some embodiments, naked antibodies are intact antibodies, while in other embodiments, naked antibodies are antigen-binding fragments of intact antibodies, such as Fab antibodies.
[0166] In this invention, the term "conjugated antibody" refers to an antibody that can associate with a pharmaceutically acceptable carrier or diluent, which may be a monoclonal antibody, a chimeric antibody, a humanized antibody, or a human antibody.
[0167] In this invention, the term "monoclonal antibody" refers to an antibody derived from a single clone (including any eukaryotic, prokaryotic, or phage clone), but is not limited to the method of producing the antibody.
[0168] In this invention, the term "biantibody" refers to a bivalent, bispecific antibody that can bind to different epitopes on the same or different antigens.
[0169] In this invention, the term "smallest unit of antibody recognition" refers to the smallest unit of antigen that an antibody can recognize in an antigen-antibody binding reaction.
[0170] In this invention, the terms "peptide molecule," "polypeptide," and "peptide" are used interchangeably and generally refer to polymers of amino acid residues. The term "fusion protein" generally refers to a polypeptide having at least two parts covalently linked together. Each part can be a polypeptide with different properties. These properties can be biological properties, such as in vitro or in vivo activity. They can also be simple chemical or physical properties, such as binding to target molecules, catalysis of reactions, etc. The two parts can be directly linked by a single peptide bond or through a peptide linker.
[0171] In this invention, the term "nucleic acid molecule" generally refers to a nucleotide, deoxyribonucleotide or ribonucleotide of any length in its isolated form, or an analogue isolated from its natural environment or synthesized artificially.
[0172] In this invention, the proteins, polypeptides, and / or amino acid sequences involved should also be understood to include at least the following range: variants or homologs that have the same or similar functions as the said protein or polypeptide.
[0173] In this invention, the variant can be, for example, a protein or polypeptide that has undergone substitution, deletion, or addition of one or more amino acids in the amino acid sequence of the protein and / or the polypeptide (e.g., an antibody or fragment thereof that specifically binds to IL-11 or TSLP protein). For example, the functional variant may comprise a protein or polypeptide that has undergone amino acid alterations through substitution, deletion, and / or insertion of at least one, such as 1-30, 1-20, or 1-10, or even 1, 2, 3, 4, or 5 amino acids. The functional variant may substantially retain the biological properties of the protein or polypeptide prior to the alteration (e.g., substitution, deletion, or addition). For example, the functional variant may retain at least 60%, 70%, 80%, 90%, or 100% of the biological activity (e.g., antigen-binding capacity) of the protein or polypeptide prior to the alteration. For example, the substitution may be a conserved substitution.
[0174] In this invention, the homolog can be a protein or polypeptide having at least about 85% (e.g., having at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 95%, about 96%, about 97%, about 98%, about 99% or higher) sequence homology with the amino acid sequence of the protein and / or the polypeptide (e.g., an antibody that specifically binds to IL-11 or TSLP protein or a fragment thereof).
[0175] In this invention, homology generally refers to the similarity, resemblance, or association between two or more sequences. The "sequence homology percentage" can be calculated as follows: Two sequences to be aligned are compared in a comparison window, and the number of positions in the two sequences containing the same nucleic acid bases (e.g., A, T, C, G, I) or the same amino acid residues (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, and Met) is determined to obtain the number of matching positions. The number of matching positions is divided by the total number of positions in the comparison window (i.e., the window size), and the result is multiplied by 100 to produce the sequence homology percentage. The alignment performed to determine the sequence homology percentage can be implemented in various ways known in the art.
[0176] In this invention, the term "vector" generally refers to a nucleic acid delivery vehicle into which a polynucleotide encoding a protein can be inserted, thereby enabling the protein to be expressed. Vectors can be transformed, transduced, or transfected into host cells, allowing the genetic material elements they carry to be expressed within the host cells. For example, vectors may include: plasmids; phage particles; Cosmids; artificial chromosomes such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), or P1-derived artificial chromosomes (PAC); bacteriophages such as λ phage or M13 phage; and animal viruses. Animal viruses used as vectors may include retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomaviruses (such as SV40). A vector may contain multiple elements controlling expression, including promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, the vector may contain a replication initiation site. The carrier may also include components that help it enter the cell, such as viral particles, liposomes, or protein coats, but not only these substances.
[0177] In this invention, the term "cell" generally refers to a single cell, cell line, or cell culture that may be or is already a recipient of a subject plasmid or vector, including the nucleic acid molecules or vectors described in this invention. Cells may include the progeny of a single cell. Due to natural, accidental, or intentional mutations, the progeny may not necessarily be identical to the original parent cell (in the morphology of total DNA complements or in the genome). Cells may include cells transfected in vitro using the vectors described in this invention. Cells may be bacterial cells (e.g., *E. coli*), yeast cells, or other eukaryotic cells, such as COS cells, Chinese hamster ovary (CHO) cells, CHO-K1 cells, LNCAP cells, HeLa cells, HEK293 cells, COS-1 cells, and NSO cells. In some embodiments, the cells are mammalian cells. In some embodiments, the mammalian cells are HEK293 cells.
[0178] In this invention, the term "chimeric antigen receptor" (CAR) generally refers to a recombinant polypeptide comprising at least an extracellular domain, a transmembrane region, and an intracellular domain that specifically bind to an antigen or target. For example, a hinge region may be included between the extracellular domain and the transmembrane region. For example, the chimeric antigen receptor may include a signal peptide. The binding of the extracellular domain of the CAR to the target antigen on the surface of the target cell leads to CAR clustering and delivers activation stimuli to CAR-containing cells. The CAR redirects the specificity of immune effector cells and triggers proliferation, cytokine production, phagocytosis, and / or production of molecules capable of mediating cell death expressing the target antigen in a major histocompatibility (MHC)-independent manner. For example, the extracellular structure may include the antigen-binding protein described above. For example, the extracellular structure may specifically bind IL-11 and / or TSLP.
[0179] In this invention, the term "pharmaceutical combination" generally refers to a combination containing at least two active ingredients / therapeutic agents. In some embodiments, each active ingredient / therapeutic agent may be prepared as an independent formulation (solid, liquid, gel, etc.); in some embodiments, each active ingredient / therapeutic agent may be present in different containers; and may be formulated simultaneously or separately with suitable carriers to form desired formulations as needed; in some embodiments, each active ingredient / therapeutic agent may be from different sources; and in some embodiments, each active ingredient / therapeutic agent may be present in the form of a mixture.
[0180] In this invention, the term "pharmaceutical composition" generally refers to a composition for the prevention / treatment of a disease or condition. The pharmaceutical composition may comprise the isolated antigen-binding protein described in this invention, the nucleic acid molecule described in this invention, the carrier described in this invention, and / or the cell described in this invention, and optionally a pharmaceutically acceptable adjuvant. Furthermore, the pharmaceutical composition may also comprise suitable formulations of one or more (pharmaceutically effective) carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers, and / or preservatives. The acceptable components of the composition are preferably non-toxic to the recipient at the dosage and concentration used. The pharmaceutical compositions of this invention include, but are not limited to, liquid, freeze-dried, and lyophilized compositions.
[0181] In this invention, the term "pharmaceutically acceptable carrier" generally includes pharmaceutically acceptable carriers, excipients, or stabilizers that are non-toxic to cells or mammals exposed thereto at the doses and concentrations employed. Physiologically acceptable carriers may include, for example, buffers, antioxidants, low molecular weight (less than about 10 residues) peptides, proteins, hydrophilic polymers, amino acids, monosaccharides, disaccharides and other carbohydrates, chelating agents, sugar alcohols, salt-forming anti-charge ions such as sodium; and / or nonionic surfactants.
[0182] In this invention, the term "subject" generally refers to a human or non-human animal, including but not limited to cats, dogs, horses, pigs, cows, sheep, rabbits, mice, rats, or monkeys.
[0183] In this invention, the term "comprising" generally means including, encompassing, containing, or including. In some cases, it also means "as" or "consisting of".
[0184] In this invention, the term "about" generally refers to a variation within a range of 0.5% to 10% above or below a specified value, such as a variation within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value.
[0185] In this invention, the term "treatment" ("treat", "treating", "treatment", etc.) means to alleviate symptoms, eliminate the cause of symptoms on a temporary or permanent basis, or prevent or slow the onset of symptoms of the mentioned condition or disease.
[0186] In this invention, the terms "preventing" or "prevention" refer to reducing the likelihood that a subject will develop a disease, condition, or symptom, wherein the subject does not have a disease, condition, or symptom but is at risk of developing or is susceptible to developing a disease, condition, or symptom.
[0187] In this invention, the terms "effective amount" or "therapeutic effective amount" are used interchangeably herein and refer to an amount sufficient to achieve a specific biological outcome or to modulate or improve symptoms or the duration of symptom onset in a subject. The effective amount for a particular subject can vary depending on factors such as the condition being treated, the subject's overall health status, the method, route, and dosage of administration, and the severity of side effects. When combined, the effective amount is proportional to the combination of components, and the effect is not limited to any single component.
[0188] In this invention, the term "fibrotic disease" or "fibrosis" refers to a condition involving the formation of excessive fibrous connective tissue in an organ or tissue. Exemplary fibrotic diseases include pulmonary fibrosis, liver fibrosis (e.g., fibrosis associated with cirrhosis (e.g., alcoholic cirrhosis, viral cirrhosis, post-hepatitis C cirrhosis, and primary biliary cirrhosis), schistosomiasis, cholangitis (e.g., sclerosing cholangitis), and autoimmune hepatitis), renal fibrosis (e.g., tubulointerstitial fibrosis, scleroderma, diabetic nephritis, and glomerulonephritis), and skin fibrosis (e.g., scleroderma, hypertrophic and keloid scarring, renal fibrotic dermatitis, and...). Fibrosis can be caused by various factors, including burns, myelofibrosis, neurofibromatosis, fibroma, intestinal fibrosis and surgically induced fibrotic adhesions, cardiac fibrosis (e.g., fibrosis associated with myocardial infarction), vascular fibrosis (e.g., fibrosis associated with arterial restenosis and atherosclerosis after angioplasty), ocular fibrosis (e.g., fibrosis associated with cataract surgery), proliferative vitreoretinopathy and retroorbital fibrosis), and myelofibrosis (e.g., idiopathic myelofibrosis and drug-induced myelofibrosis). Fibrosis can be organ-specific or systemic (e.g., systemic sclerosis and fibrosis associated with GVHD). Examples of pulmonary fibrosis include, for example, pulmonary or lung fibrosis associated with idiopathic pulmonary fibrosis, fibrosis with collagen vascular disease, Hermansky-Pudrag syndrome, adult respiratory distress syndrome, nonspecific interstitial pneumonia, respiratory bronchiolitis, sarcoidosis, histiocytosis X, obliterative bronchiolitis, and cryptogenic organizing pneumonia.
[0189] In this invention, the term "asthma" refers to a common and potentially serious chronic disease of the respiratory tract, characterized by airway inflammation and constriction resulting in symptoms such as wheezing, shortness of breath, chest tightness, and cough, which vary over time in their occurrence, frequency, intensity, and response to therapy.
[0190] In this invention, the term "asthma" refers to all phenotypes and endotypes of asthma at all severity levels, regardless of disease control status, such as non-allergic asthma, allergic asthma, mild asthma, moderate asthma, severe asthma, moderate to severe asthma, uncontrolled asthma, non-eosinophilic asthma, hypoeosinophilic asthma, hypereosinophilic (eosinophilic) asthma, bronchial asthma, exercise-induced asthma, occupational asthma, and asthma induced by bacterial or viral infection.
[0191] In this invention, the terms "idiopathic pulmonary fibrosis" (IPF) refer to restrictive lung diseases characterized by progressive interstitial fibrosis of the lung parenchyma. The main manifestation is progressively worsening dyspnea, accompanied by restrictive ventilatory dysfunction and impaired gas exchange, leading to hypoxemia and even respiratory failure, with a poor prognosis.
[0192] In this invention, the terms "chronic obstructive pulmonary disease," "COPD," etc., refer to chronic inflammatory lung diseases that cause obstruction of airflow from the lungs. Symptoms of COPD include shortness of breath, cough, mucus (sputum) production, and wheezing. COPD is characterized by poor reversibility and progressive airway obstruction. The two most common COPD conditions are chronic bronchitis and emphysema. Chronic bronchitis is a long-term inflammation of the bronchi, leading to increased mucus production and other changes. These changes can cause breathing problems, frequent infections, cough, and asynchrony. Chronic bronchitis is associated with the proliferation and hypertrophy of mucus-secreting glands in the submucosa of the large cartilaginous airways. Goblet cell proliferation, inflammatory cell infiltration of the mucosa and submucosa, edema, fibrosis, mucus blockage, and increased smooth muscle are found in both terminal bronchioles and respiratory bronchioles. Small airways are known to be the primary site of airway obstruction. Emphysema is characterized by the destruction of alveolar walls and loss of lung elasticity. Emphysema is a chronic lung disease in which alveoli may be destroyed, narrowed, collapsed, stretched, and / or overinflated. This can lead to a decline in respiratory function and shortness of breath. Damage to the alveoli is irreversible and results in permanent “holes” in the lung tissue. The main pathophysiology of COPD is irreversible airway obstruction with progressive decline in lung function, especially in patients with persistent exposure to risk factors such as cigarette smoke, biomass smoke exposure, air pollution, particulate exposure, asthma and airway hyperresponsiveness, chronic bronchitis, and infections.
[0193] In this invention, the terms "atopic dermatitis," "AD," or "AD" refer to a chronic, relapsing, inflammatory skin condition. The term "atopic dermatitis" includes, but is not limited to, AD caused by or associated with epidermal barrier dysfunction, allergic reactions (e.g., allergic reactions to certain foods, pollen, mold, dust mites, animals, etc.), radiation exposure, and / or asthma.
[0194] Invention Details
[0195] IL-11 antibody and / or antigen-binding fragment
[0196] On the one hand, the present invention provides IL-11 antibody and / or antigen-binding fragments.
[0197] In this invention, the IL-11 antibody and / or antigen-binding fragment may contain at least one CDR in the antibody heavy chain variable region VH as shown in SEQ ID NO:4.
[0198] In this invention, the IL-11 antibody and / or antigen-binding fragment may contain HCDR1, and the amino acid sequence of HCDR1 is shown in SEQ ID NO:1.
[0199] In this invention, the IL-11 antibody and / or antigen-binding fragment may contain HCDR2, and the amino acid sequence of HCDR2 is shown in SEQ ID NO:2.
[0200] In this invention, the IL-11 antibody and / or antigen-binding fragment may contain HCDR3, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:3.
[0201] In this invention, the IL-11 antibody and / or antigen-binding fragment may comprise HCDR1, HCDR2 and HCDR3, wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO:1, the amino acid sequence of HCDR2 is shown in SEQ ID NO:2 and the amino acid sequence of HCDR3 is shown in SEQ ID NO:3.
[0202] In this invention, the IL-11 antibody and / or antigen-binding fragment may contain at least one CDR in the VH described in this invention. The CDR can be obtained according to any partitioning method.
[0203] For example, the CDR of the IL-11 antibody and / or antigen-binding fragment can be delimited using the Kabat method.
[0204] In this invention, the antibody framework region (FR) refers to the portion of the antibody variable region located between more divergent (i.e., hypervariable) CDRs. Such framework regions are typically referred to as frames 1 to 4 (FR1, FR2, FR3, and FR4) and provide a backbone for presenting six CDRs (three from the heavy chain and three from the light chain) in three-dimensional space to form an antigen-binding surface.
[0205] In this invention, the IL-11 antibody and / or antigen-binding fragment may include a variable region VH, and the amino acid sequence of the VH is shown in SEQ ID NO:4.
[0206] In this invention, the antigen-binding fragment may be selected from Fab, Fab', F(ab)2, Fv fragment, F(ab')2, scFv, di-scFv, VHH and / or dAb.
[0207] In this invention, the antibody is selected from the group consisting of monoclonal antibodies, chimeric antibodies, humanized antibodies, and fully human antibodies.
[0208] In this invention, the IL-11 antibody and / or antigen-binding fragment may contain VHH, and the amino acid sequence of VHH is shown in SEQ ID NO:4.
[0209] In this invention, the IL-11 antibody and / or antigen-binding fragment may include an antibody heavy chain constant region. The antibody heavy chain constant region may be derived from the human IgG heavy chain constant region. In some embodiments, the isolated antigen-binding protein may include an antibody heavy chain constant region, and the antibody heavy chain constant region may be derived from the human IgG1 heavy chain constant region. In some embodiments, the isolated antigen-binding protein may include an antibody heavy chain constant region, and the antibody heavy chain constant region may be derived from the human IgG heavy chain constant region and modified with amino acid mutations.
[0210] Furthermore, it should be noted that the isolated antigen-binding protein of this invention may contain heavy and / or light chain sequences with one or more conserved sequence modifications. "Conserved sequence modification" refers to amino acid modifications that do not significantly affect or alter antibody binding properties. Such conserved modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into the isolated antigen-binding protein of this invention using standard techniques known in the art, such as point mutations and PCR-mediated mutations. Conserved amino acid substitution involves replacing an amino acid residue with an amino acid residue having a similar side chain. Groups of amino acid residues with similar side chains are known in the art. These amino acid residue groups include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), nonpolar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In some embodiments, one or more amino acid residues in the CDR region of the isolated antigen-binding protein described in this invention may be replaced with other amino acid residues from the same side chain group. Those skilled in the art will recognize that some conserved sequence modifications do not result in the loss of antigen binding.
[0211] TSLP antibody and / or antigen-binding fragment
[0212] On the other hand, the present invention provides TSLP antibodies and / or antigen-binding fragments.
[0213] In this invention, the TSLP antibody and / or antigen-binding fragment may contain at least one CDR in the antibody heavy chain variable region VH as shown in SEQ ID NO:14.
[0214] In this invention, the TSLP antibody and / or antigen-binding fragment may contain HCDR1, the amino acid sequence of which is shown in SEQ ID NO:8.
[0215] In this invention, the TSLP antibody and / or antigen-binding fragment may contain HCDR2, the amino acid sequence of which is shown in SEQ ID NO:9.
[0216] In this invention, the TSLP antibody and / or antigen-binding fragment may contain HCDR3, the amino acid sequence of which is shown in SEQ ID NO:10.
[0217] In this invention, the TSLP antibody and / or antigen-binding fragment may comprise HCDR1, HCDR2, and HCDR3. For example, the amino acid sequence of HCDR1 of the isolated antigen-binding protein is shown in SEQ ID NO:8, the amino acid sequence of HCDR2 is shown in SEQ ID NO:9, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:10.
[0218] In this invention, the TSLP antibody and / or antigen-binding fragment may contain at least one CDR in the variable region VL of the antibody light chain as shown in SEQ ID NO:15.
[0219] In this invention, the TSLP antibody and / or antigen-binding fragment may contain LCDR1, the amino acid sequence of which is shown in SEQ ID NO:11.
[0220] In this invention, the TSLP antibody and / or antigen-binding fragment may contain LCDR2, the amino acid sequence of which is shown in SEQ ID NO:12(GAR).
[0221] In this invention, the TSLP antibody and / or antigen-binding fragment may contain LCDR3, the amino acid sequence of which is shown in SEQ ID NO:13.
[0222] In this invention, the TSLP antibody and / or antigen-binding fragment may comprise LCDR1, LCDR2, and LCDR3. For example, the amino acid sequence of LCDR1 of the isolated antigen-binding protein is shown in SEQ ID NO:11, the amino acid sequence of LCDR2 is shown in SEQ ID NO:12 (GAR), and the amino acid sequence of LCDR3 is shown in SEQ ID NO:13.
[0223] In this invention, the TSLP antibody and / or antigen-binding fragment may comprise HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3. For example, the amino acid sequence of the isolated antigen-binding protein HCDR1 described in this invention is shown in SEQ ID NO:8, the amino acid sequence of HCDR2 is shown in SEQ ID NO:9, the amino acid sequence of HCDR3 is shown in SEQ ID NO:10, the amino acid sequence of LCDR1 is shown in SEQ ID NO:11, the amino acid sequence of LCDR2 is shown in SEQ ID NO:12 (GAR), and the amino acid sequence of LCDR3 is shown in SEQ ID NO:13.
[0224] In this invention, the TSLP antibody and / or antigen-binding fragment may contain a VH, which may contain the amino acid sequence shown in SEQ ID NO:14.
[0225] In this invention, the TSLP antibody and / or antigen-binding fragment may contain a VL, which may contain the amino acid sequence shown in SEQ ID NO:15.
[0226] In this invention, the TSLP antibody and / or antigen-binding fragment may include the VH and VL.
[0227] For example, the VH may contain the amino acid sequence shown in SEQ ID NO:14, and the VL may contain the amino acid sequence shown in SEQ ID NO:15.
[0228] In this invention, the TSLP antibody / isolated TSLP antigen-binding protein may contain at least one CDR from the VH described in this invention. In this invention, the isolated antigen-binding protein may contain at least one CDR from the VL described in this invention. The CDR can be obtained according to any partitioning method.
[0229] For example, the CDR of the TSLP antibody / isolated TSLP antigen-binding protein can be delimited using the IMGT method.
[0230] In this invention, the TSLP antibody and / or antigen-binding fragment may include an antibody heavy chain constant region. The antibody heavy chain constant region may be derived from the human IgG heavy chain constant region. In some embodiments, the isolated antigen-binding protein may include an antibody heavy chain constant region, and the antibody heavy chain constant region may be derived from the human IgG1 heavy chain constant region.
[0231] In this invention, the TSLP antibody and / or antigen-binding fragment may include an antibody light chain constant region. The antibody light chain constant region may be derived from the human Igκ constant region.
[0232] In some embodiments, the antigen-binding fragment may include Fab, Fab', Fv fragments, F(ab')2, F(ab)2, scFv, di-scFv, and / or dAb.
[0233] In some embodiments, the antibody may include a monoclonal antibody, a chimeric antibody, a humanized antibody, and / or a fully human antibody.
[0234] Multispecific molecules
[0235] On the other hand, the present invention provides a multispecific molecule comprising a first binding domain capable of binding IL-11. In the present invention, the first binding domain of the multispecific antibody may comprise the IL-11 antibody and / or antigen-binding fragment described above.
[0236] In this invention, the multispecific antibody may further include a second targeting portion, which may contain a second binding domain capable of binding TSLP. In this invention, the second binding domain of the multispecific antibody may contain the TSLP antibody and / or antigen-binding fragment described above.
[0237] In this invention, the first binding domain capable of binding IL-11 and the second binding domain capable of binding TSLP include Fab, Fab', F(ab)2, Fv fragment, F(ab')2, scFv, di-scFv, and / or dAb. For example, the first binding domain capable of binding IL-11 and the second binding domain capable of binding TSLP are selected from the group consisting of monoclonal antibodies, chimeric antibodies, humanized antibodies, and fully human antibodies.
[0238] In this invention, the multispecific molecule can be a bispecific antibody. A bispecific antibody (bsAb) can be a non-natural antibody that simultaneously targets two different antigens or proteins, blocking one or more signaling pathways and stimulating a specific immune response. Its specificity and dual functionality play an increasingly important role in tumor immunotherapy, making it a research hotspot in antibody engineering for tumor treatment worldwide. Studies have shown that bispecific antibodies in tumor immunotherapy mainly mediate the killing of tumors by immune cells; bind to two targets, block signaling pathways, and exert unique or overlapping functions, effectively preventing drug resistance; possess strong specificity, targeting ability, and reduced off-target toxicity; and effectively reduce treatment costs. Therefore, using bispecific antibody drugs can reduce the chance of tumor cell escape, eliminate tumor cells, and improve efficacy. Bispecific antibodies can be prepared through hybridoma cells, chemical conjugation, recombinant genes, etc. Among them, recombinant gene technology has high flexibility in terms of binding sites and yield. The main structures of bispecific antibodies are bispecific antibodies containing Fc fragments (IgG-like bispecific antibodies, which have Fc-mediated effector functions) and bispecific antibodies without Fc fragments (non-IgG-like bispecific antibodies, which exert their effects through antigen binding force and have advantages such as small molecular weight and low immunogenicity).
[0239] In this invention, in the multispecific molecule, the first binding domain targeting IL-11 and the second binding domain targeting TSLP can be directly or indirectly linked. For example, the C-terminus of the first binding domain targeting IL-11 is linked to the N-terminus of the second binding domain targeting TSLP. For example, the C-terminus of the first binding domain targeting IL-11 is linked to the N-terminus of the heavy chain variable region (VH) of the second binding domain targeting TSLP. For example, the N-terminus of the first binding domain targeting IL-11 is linked to the C-terminus of the second binding domain targeting TSLP. For example, the N-terminus of the first binding domain targeting IL-11 is linked to the C-terminus of the heavy chain constant region of the second binding domain targeting TSLP. For example, the first binding domain targeting IL-11 and the second binding domain targeting TSLP are linked by a linker. The linker may contain a peptide linker. For example, the linker may contain an amino acid sequence of (GGGGS)n, where n is any positive integer from 0 to 10. For example, the linker contains the amino acid sequence shown in GGGGSGGGGS (SEQ ID NO:5).
[0240] In this invention, the multispecific molecule may comprise two first binding domains capable of targeting IL-11, wherein the two first binding domains capable of targeting IL-11 are directly or indirectly connected to the N-terminus of the two heavy chains of the second binding domain targeting TSLP. For example, the two first binding domains capable of targeting IL-11 are directly or indirectly connected to the C-terminus of the two heavy chains of the second binding domain targeting TSLP. For example, the two first binding domains capable of targeting IL-11 are directly or indirectly connected to the N-terminus of the two heavy chains of the second binding domain targeting TSLP.
[0241] In this invention, the multispecific molecule may comprise a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain may comprise a heavy chain containing a first binding domain capable of targeting IL-11 and a second binding domain capable of targeting TSLP, and the second polypeptide chain may comprise a light chain containing the second binding domain. In this invention, the multispecific molecule may comprise two first polypeptide chains and two second polypeptide chains. For example, the first polypeptide chain may contain the N-terminus of the heavy chain containing the first binding domain capable of targeting IL-11 and the second binding domain capable of targeting TSLP directly or indirectly linked. For example, the first polypeptide chain may contain the C-terminus of the heavy chain containing the first binding domain capable of targeting IL-11 and the second binding domain capable of targeting TSLP directly or indirectly linked. For example, the first polypeptide chain may contain the heavy chain containing the first binding domain capable of targeting IL-11 and the second binding domain capable of targeting TSLP linked by a linker. For example, the first polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:18. For example, the second polypeptide chain may comprise the amino acid sequence shown in SEQ ID NO:19.
[0242] In this invention, the structure of the multispecific molecule can be VHH-IgG, meaning that the N-terminus or C-terminus of both heavy chains of an IgG antibody targeting the TSLP antigen is linked to the VHH fragment of another nanobody targeting the IL-11 antigen. In this invention, the structure of the multispecific molecule can be either a configuration where the VHH is linked to the N-terminus of the IgG antibody or a configuration where the VHH is linked to the C-terminus of the IgG antibody heavy chain. For example, the structure of the multispecific molecule can be as shown in Figure 1.
[0243] Drug combination
[0244] On the other hand, the present invention provides a drug combination comprising a first antibody capable of targeting IL-11 and a second antibody targeting TSLP.
[0245] In this invention, the first antibody capable of targeting IL-11 may comprise the IL-11 antibody and / or antigen-binding fragment described above, or it may be one or more known IL-11 antibodies. For example, the antibody in patent WO2023 / 143556A1.
[0246] In this invention, the second antibody capable of targeting TSLP may comprise the TSLP antibody and / or antigen-binding fragment described above, or may be one or more known TSLP antibodies, such as Tezepelumab.
[0247] In this invention, the pharmaceutical combination can refer to a product resulting from a mixture or combination of more than one active ingredient, and includes fixed and non-fixed combinations of active ingredients. A fixed combination can refer to the simultaneous administration of the active ingredient (e.g., the IL-11 antibody, TSLP antibody, and multispecific molecules described in this invention) and one or more combination partners to a patient in the form of a single entity or dose. A non-fixed combination can refer to the simultaneous, co-occurring, or sequential (without a specific time limit) administration of the active ingredient and one or more combination partners to a patient as separate entities, wherein such administration provides a therapeutically effective level of the two compounds in the patient's body. The latter also applies to cocktail therapies, such as the administration of three or more active ingredients.
[0248] One or more isolated nucleic acid molecules, vectors, and cells
[0249] In another aspect, the present invention also provides isolated one or more nucleic acid molecules. These one or more nucleic acid molecules may encode the multispecific molecule described in the present invention. For example, each of the one or more nucleic acid molecules may encode the complete multispecific molecule or a portion thereof (e.g., a first binding domain targeting IL-11, a second binding domain targeting TSLP, an IL-11 antibody, a TSLP antibody, HCDR1-3, LCDR1-3, VL, VH, one or more of the light or heavy chains).
[0250] The nucleic acid molecules described in this invention can be isolated. For example, they can be produced or synthesized by: (i) in vitro amplification, such as by polymerase chain reaction (PCR), (ii) clonal recombination, (iii) purification, such as separation by enzyme digestion and gel electrophoresis, or (iv) synthesis, such as by chemical synthesis. In some embodiments, the isolated nucleic acid is a nucleic acid molecule prepared by recombinant DNA technology.
[0251] In this invention, nucleic acids encoding the multispecific antibodies described herein can be prepared by a variety of methods known in the art, including but not limited to, restriction fragment manipulation or overlap extension PCR using synthetic oligonucleotides, for details of which can be found in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausube et al., Current Protocols in Molecular Biology, Greene Publishing and Wiley-Interscience, New York NY, 1993.
[0252] In another aspect, the present invention provides one or more vectors comprising one or more nucleic acid molecules as described herein. Each vector may contain one or more of the nucleic acid molecules described herein. Furthermore, the vector may also contain other genes, such as marker genes that allow selection of the vector in appropriate host cells and under appropriate conditions. Additionally, the vector may contain expression control elements that allow the coding region to be correctly expressed in an appropriate host. Such control elements are well known to those skilled in the art and may include, for example, promoters, ribosome binding sites, enhancers, and other control elements regulating gene transcription or mRNA translation. In some embodiments, the expression control sequence is a tunable element. The specific structure of the expression control sequence may vary depending on the species or cell type and function, but typically includes 5' non-transcriptional sequences and 5' and 3' non-translational sequences, respectively, involved in transcription and translation initiation, such as TATA boxes, capping sequences, CAAT sequences, etc. For example, the 5' non-transcriptional expression control sequence may contain a promoter region, which may contain a promoter sequence for transcriptionally controlling functionally linked nucleic acids. The expression control sequence may also include enhancer sequences or upstream activator sequences. In this invention, suitable promoters may include, for example, promoters for SP6, T3, and T7 polymerases, human U6RNA promoters, CMV promoters, and their artificial hybrid promoters (such as CMV), wherein a portion of the promoter may be fused to a portion of a promoter of another cellular protein (such as human GAPDH, glyceraldehyde-3-phosphate dehydrogenase) gene, and may or may not contain additional introns. One or more nucleic acid molecules described in this invention can be operatively linked to the expression control element. The vector may include, for example, plasmids, granules, viruses, bacteriophages, or other vectors commonly used in, for example, genetic engineering. For example, the vector is an expression vector. In another aspect, this invention provides cells that may contain one or more nucleic acid molecules described in this invention and / or one or more vectors described in this invention. In some embodiments, each or each cell may contain one or more nucleic acid molecules or vectors described in this invention. In some embodiments, each or each cell may contain multiple (e.g., two or more) or more types (e.g., two or more) nucleic acid molecules or vectors described in this invention. For example, the vector described in this invention can be introduced into the cells, such as eukaryotic cells, including plant cells, fungal or yeast cells, etc. The vector described in this invention can be introduced into the cells using methods known in the art, such as electroporation, lipofectine transfection, lipofectamin transfection, etc.
[0253] Preparation method
[0254] In another aspect, the present invention provides a method for preparing the aforementioned multispecific molecules. The method may include culturing the cells of the present invention under conditions that allow the multispecific molecules to be expressed. For example, this can be achieved by using suitable culture media, suitable temperatures, and culture times, methods known to those skilled in the art.
[0255] Humanized antibodies can be selected from any type of immunoglobulin, including IgM, IgD, IgG, IgA, and IgE. In this invention, the antibody is an IgG antibody, using the IgG1 subtype. Similarly, any class of light chains can be used in the compounds and methods described herein. Specifically, κ, λ chains, or variants thereof, can be used in the compounds and methods of this invention.
[0256] The DNA sequences of the multispecific molecules or fragments thereof of the present invention can be obtained using conventional techniques, such as PCR amplification or genomic library screening. Furthermore, the coding sequences of the light and heavy chains can be fused together to form single-chain antibodies.
[0257] Once the relevant sequence is obtained, it can be obtained in large quantities using recombination methods. This typically involves cloning it into a vector, transforming it into cells, and then isolating the sequence from the proliferated cells using conventional methods.
[0258] In addition, sequences can be synthesized artificially, especially when the fragment length is short. Typically, long sequences are obtained by first synthesizing multiple small fragments and then ligating them. The nucleic acid molecule can then be introduced into various existing DNA molecules (or vectors) and cells known in the art.
[0259] The present invention also relates to vectors comprising the aforementioned suitable nucleic acid molecules and suitable promoters or control sequences. These vectors can be used to transform suitable host cells to enable them to express proteins. Host cells can be prokaryotic cells, such as bacterial cells; lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. For example, animal cells may include (but are not limited to): CHO-S, CHO-K1, and HEK-293 cells.
[0260] The cell transformation steps using recombinant DNA described in this invention can be performed using techniques well known in the art. The obtained transformants can be cultured using conventional methods, and the transformants express the polypeptide encoded by the nucleic acid molecule of this invention. Depending on the cells used, they are cultured in conventional culture media under suitable conditions. Typically, the transformed cells are cultured under conditions suitable for the expression of the multispecific molecules of this invention. Then, the multispecific antibodies of this invention are purified using conventional immunoglobulin purification steps, such as protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, ion exchange chromatography, hydrophobic chromatography, molecular sieve chromatography, or affinity chromatography, and other conventional separation and purification methods well known to those skilled in the art.
[0261] The resulting monoclonal antibodies or multispecific molecules can be identified using conventional methods. For example, the binding specificity of monoclonal antibodies or multispecific antibodies can be determined using immunoprecipitation or in vitro binding assays (such as flow cytometry (FACS), radioimmunoassay (RIA), or enzyme-linked immunosorbent assay (ELISA)).
[0262] Pharmaceutical Composition
[0263] On the other hand, the present invention also provides a composition. In some cases, the composition may be a pharmaceutical composition containing the multispecific antibody of the present invention and a pharmaceutically acceptable carrier. Typically, these substances are formulated in a non-toxic, inert, and pharmaceutically acceptable aqueous carrier medium. The formulated pharmaceutical composition can be administered via conventional routes.
[0264] The pharmaceutical compositions described herein can be directly used to bind IL-11 or TSLP protein molecules, and are therefore suitable for the prevention and treatment of IL-11 or TSLP-related diseases. The pharmaceutical compositions of this invention may contain a safe and effective amount of the antigen-binding protein described herein, as well as a pharmaceutically acceptable adjuvant (which may include a carrier or excipient). The pharmaceutical formulation should be matched to the route of administration. The multispecific antibody or pharmaceutical composition described herein can be formulated, administered, and applied in accordance with good medical practice. Considerations in this context include the specific disease being treated, the specific mammal being treated, the clinical symptoms of the individual patient, the etiology of the disease, the site of drug delivery, the method of administration, the administration schedule, and other factors known to the medical practitioner.
[0265] Uses and methods
[0266] On the other hand, the present invention also provides a method for blocking the binding of TSLP to the receptor TSLPR / IL7Ra complex, the method comprising administering the multispecific molecule and / or the drug combination described herein.
[0267] On the other hand, the present invention also provides a method for inhibiting the production of TARC (thymus and activation regulatory chemokines), the method comprising administering the multispecific antibody and / or the drug combination described herein.
[0268] On the other hand, the present invention provides the use of the aforementioned multispecific molecules, the aforementioned drug combinations, the aforementioned nucleic acid molecules, the aforementioned carriers, the aforementioned cells, and / or the aforementioned drug compositions in the preparation of pharmaceuticals. The pharmaceuticals are used to prevent, alleviate, and / or treat diseases or conditions, such as IL-11-related diseases, such as TSLP-related diseases. In some cases, the disease may be a fibrotic disease, an inflammatory disease, or a tumor.
[0269] On the other hand, the present invention provides the use of the aforementioned multispecific molecules, the aforementioned drug combinations, the aforementioned nucleic acid molecules, the aforementioned carriers, the aforementioned cells, and / or the aforementioned drug compositions in the treatment / alleviation of diseases.
[0270] On the other hand, the present invention provides the aforementioned multispecific molecules, the aforementioned drug combinations, the aforementioned nucleic acid molecules, the aforementioned carriers, the aforementioned cells, and / or the aforementioned drug compositions for treating / alleviating diseases.
[0271] In some cases, the disease may be a fibrotic disease, an inflammatory disease, or a tumor.
[0272] In some cases, the inflammatory disease can be a type 2 inflammatory disease; the inflammatory disease can be a Th2 cell-related disease; the inflammatory disease can be asthma, atopic dermatitis, etc.
[0273] In some cases, the fibrosis is fibrosis of the heart, liver, kidneys, lungs, skin, or eyes. In some cases, the fibrosis is present in the lungs, for example, pulmonary fibrosis, asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, etc. In other cases, the fibrosis is present in the skin, for example, the fibrosis can be atopic dermatitis, etc.
[0274] To further illustrate the technical means and effects of this invention, the following description, in conjunction with embodiments and accompanying drawings, provides a further explanation of the invention. It is understood that the specific embodiments described herein are merely illustrative of the invention and not intended to limit it.
[0275] Where specific techniques or conditions are not specified in the examples, they shall be performed in accordance with the techniques or conditions described in the literature in this field, or in accordance with the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased through legitimate channels.
[0276] Example
[0277] Example 1: IL-11 / TSLP Bispecific Antibody
[0278] The IL-11 / TSLP bispecific antibody (I700021) is shown in Figure 1. Its specific sequence information is as follows:
[0279] Heavy chain full-length sequence, SEQ ID NO:18
[0280] Full-length light chain sequence, SEQ ID NO:19
[0281] IL-11VHH(700077) sequence, SEQ ID NO: 4
[0282] TSLP antibody (900792) heavy chain full-length sequence, SEQ ID NO: 6
[0283] TSLP antibody (900792) light chain full-length sequence, SEQ ID NO: 7
[0284] Note: The underlined and bolded areas represent the CorelDRAW (Copyright DR) area, as shown below:
[0285] Table 1 Antibody CDR Sequences
[0286] Based on the above sequence information and conventional methods in the field, a TSLP / IL-11 bispecific antibody was prepared.
[0287] Example 2: Detection of the inhibitory effect of anti-TSLP / IL-11 bispecific antibody on fibrosis and inflammation in vitro.
[0288] Studies have shown that TGF-β induces the production of fibrosis-related genes such as Collagen IV through Smad 2 / 3 signaling. During this process, Smad 2 / 3 signaling also induces the transcription, synthesis, and secretion of IL-11. IL-11 secreted by fibroblasts acts on themselves, thereby enhancing the TGF-β-induced fibrosis effect. Furthermore, in the development and progression of TGF-β-induced fibrosis, TGF-β promotes IL-11 production, and IL-11 autocrine activation of the ERK-MAPK signaling pathway promotes fibroblast proliferation and fibrin production. IL-11 can promote type II inflammatory responses by inducing IL-33 expression. IL-33, as an alarmist, has a nuclear localization sequence that normally positions it in the perinuclear region, preventing spontaneous extracellular secretion.
[0289] Therefore, in this embodiment, the inhibitory activity of the antibody against TGF-beta-induced NHDF cell fibrosis was analyzed using immunofluorescence and flow cytometry, respectively. The inhibitory activity of the antibody against IL-11-induced ERK1 / 2 phosphorylation was also detected using a cell-based ELISA method to assess the inhibitory effect of the antibody on fibrosis in this invention. Furthermore, based on the characteristics of IL-33 and known reports, the peak expression of IL-33 induced by IL-11 occurs between 6 and 24 hours. We used intracellular staining via flow cytometry to detect the intracellular expression of IL-33 induced by IL-11.
[0290] 2.1 Immunofluorescence assay to detect the inhibitory activity of the antibody against TGF-beta-induced fibrosis
[0291] NHDF cells were collected, resuspended, plated, and starved overnight. Cytokine TGF-beta (Acro#TG1-H4212) was diluted to 40 ng / mL in serum-free DMEM (Gibco#11965092), and antibodies I700021, 900792, and 700077 were diluted to 100 nM and added to the cells. The cells were incubated for 48 hours. After incubation, the cells were fixed, washed, permeabilized, and then blocked. Following this, the antibody (abcam#ab6586, 1:1000) was diluted with antibody dilution buffer (Abrax#PS119) and incubated overnight at 4°C. The following day, the cells were washed three times with immunostaining washing buffer (Beyotime #P0106), and then the fluorescent secondary antibody (Jackson ImmunoResearch #111-545-003, 1:1000) was diluted with immunostaining washing buffer and incubated at room temperature in the dark for 40 minutes. After incubation, DAPI (Merck #D9542) was diluted with immunostaining washing buffer and the cells were incubated for 10 minutes. After washing five times with immunostaining washing buffer, the cells were mounted with anti-quenching mounting medium (Beyotime #P0131) and examined for fluorescence under a microscope.
[0292] The experimental results are shown in Figure 2. Immunofluorescence detection results show that the antibody of the present invention can significantly inhibit TGF-beta-induced fibrosis. Among them, the bispecific antibody I700021 in the present invention has strong blocking activity.
[0293] 2.2 Flow cytometry detection of antibody's inhibitory activity against TGF-beta-induced fibrosis
[0294] NHDF cells were collected, resuspended, plated, and starved overnight. Cytokine TGF-beta (Acro#TG1-H4212) was diluted to 40 ng / mL in serum-free DMEM (Gibco#11965092), and antibodies I700021 and 700077 were diluted to 100 nM. These were then diluted eight times in three-fold increments with TGF-beta-containing medium before being added to the cells. The cells were incubated for 24 hours. After incubation, cells were digested with trypsin (Gibco#25200056), and digestion was terminated with FACS buffer (DMEM + 1% FBS + 50 nM EDTA). Cells were then transferred and centrifuged to remove the culture supernatant. The cell pellet was fixed, washed once with Cyto-Perm (Biolegend#421002) staining and permeabilization buffer, and incubated for 15 min. After treatment, the cells were incubated with antibody diluted with Cyto-Perm (abcam#ab225143) at room temperature in the dark for 25 minutes, washed once with Cyto-Perm, washed once with FACS buffer, and then resuspended in 50 μL of FACS buffer. The fluorescence value was detected by flow cytometry.
[0295] The experimental results are shown in Figure 3. Flow cytometry results show that the bispecific antibody I700021 of this invention has better blocking activity than the parent monoclonal antibody 700077 and can inhibit TGF-beta-induced fibrosis.
[0296] 2.3 Detection of antibody activity against IL-11-induced ERK1 / 2 phosphorylation
[0297] NHDF cells were collected, resuspended, plated, and starved overnight. Cytokine IL-11 (Sino#12225-HNCE) was diluted to 100 ng / mL in serum-free DMEM (Gibco#11965092). Antibodies I700021 and 700077 were diluted to 100 nM in IL-11-containing medium, and then further diluted eight times in IL-11-containing medium at a 3-fold dilution ratio before being added to the cells. Cells were incubated for 4–6 hours. After incubation, cells were fixed, washed, permeabilized, and blocked. Following this, the antibody (CST#4370, 1:1000) was diluted with antibody dilution buffer (Yamen#PS119) and incubated overnight at 4°C. The following day, after washing three times with immunostaining wash buffer (Beyotime #P0106), the fluorescent secondary antibody (Jackson ImmunoResearch #111-545-003, 1:1000) and TRITC-phalloidin dye were diluted with immunostaining wash buffer and incubated at room temperature in the dark for 40 minutes. After incubation, the fluorescence AF-488 and TRITC were detected using a microplate reader. The experimental results are shown in Figure 4.
[0298] 2.4 Detection of antibody blocking activity against IL-11-induced IL-33 expression
[0299] A549 cells were collected and starved overnight. Cytokine IL-11 (Sino#12225-NHCE) was diluted to 100 ng / mL in serum-free DMEM (Gibco#11965092). Antibodies I700021 and 700077 were diluted to 100 nM in IL-11-containing medium, and then further diluted eight times in IL-11-containing medium at a 3-fold dilution ratio before being added to the cells. The cells were incubated for 24 hours. After incubation, the cell pellet was fixed with cell immunostaining fixative (Biolegend#420801) for 30 minutes, washed once with Cyto-Perm cytoplasmic staining permeabilization buffer (Biolegend#421002), and incubated for 15 minutes. The treated cells were then incubated with Cyto-Perm diluted antibody (abcam#ab275607) at room temperature in the dark for 25 minutes. After washing, the cells were resuspended, and fluorescence values were detected by flow cytometry.
[0300] The experimental results are shown in Figure 5. The test results show that the bispecific antibody I700021 and the parent monoclonal antibody 700077 of the present invention have strong blocking activity and can inhibit the production of IL-33 inflammatory factor induced by IL-11.
[0301] Example 3: Evaluation of the in vivo inhibitory effect of anti-TSLP / IL-11 bispecific antibody on fibrosis.
[0302] 3.1 Anti-TSLP / IL-11 bispecific antibody inhibits pulmonary fibrosis in animal models
[0303] The inhibitory effects of anti-TSLP / IL-11 bispecific antibody (I700021) on inflammation and pulmonary fibrosis were verified in a bleomycin-induced TSLP / TSLPR-targeted humanized mouse (purchased from Biocytogen) pulmonary fibrosis model, with equimolar amounts of anti-TSLP monoclonal antibody (900792) and anti-IL-11 monoclonal antibody (700077) used as controls.
[0304] Mice weighing 18-20g were selected for modeling and randomly assigned to groups based on body weight. On day D0, based on body weight, animals were administered bleomycin via intratracheal administration, followed by antibody injections twice a week for three weeks. Simultaneously, an equimolar control antibody IgG was administered as the Vehicle group. On day 21, after anesthetizing the animals with sulfadiazine (intraperitoneal injection, 25-50 mg / kg, containing 1 mg / mL toluidine), bronchoalveolar lavage fluid was collected. The lungs were first lavaged with 0.6 mL of PBS (containing 1% FBS). A second lavage was performed with an additional 0.6 mL of PBS (containing 1% FBS). A 100 μL suspension was collected to count the total number of cells in the bronchoalveolar lavage fluid (BALF).
[0305] The cells were centrifuged at 300g for 5 minutes at 4°C using BALF. The resulting cell clusters were resuspended and used for smear preparation. Wright-Giemsa staining was used to distinguish eosinophils by randomly counting the number of cells of each subtype in 200 cells under a light microscope. The left lung was fixed in neutral formaldehyde, and the entire left lung was embedded in a paraffin block. One section of the largest cross-section was prepared, stained with Masson's stain, and used for histopathological analysis of the fibrotic area.
[0306] The results are shown in Figures 6-8. Figure 6 shows the eosinophil count in BALF. Figure 7 shows the Fibronectin content in lung tissue, indicating that compared to the untreated mouse model, the antibody drug of this invention can reduce Fibronectin content and has a certain effect in reducing Fibronectin synthesis, with the effect being particularly significant after treatment with the bispecific antibody I700021. Figure 8 shows a Masson staining image of the lung. In summary, the antibody drug of this invention, especially the bispecific antibody I700021, can effectively improve pulmonary fibrosis and has a therapeutic effect.
[0307] 3.2 Anti-TSLP / IL-11 bispecific antibody improves renal fibrosis in animal models
[0308] A humanized mouse model of unilateral ureteral ligation (UUO) targeting TSLP / TSLPR was established to evaluate the biological effects of anti-TSLP / IL-11 bispecific antibodies against renal fibrosis. Based on the characteristics of the UUO animal model, an intervention strategy was adopted: postoperative administration twice weekly for 3 weeks (a total of 6 administrations). Key indicators of the operated kidney were measured. The ameliorative effect of the test antibody on renal fibrosis was evaluated using PAS staining and Masson staining, with quantitative PAS staining scores reflecting glomerular fibrosis.
[0309] Ten-week-old female TSLP / TSLPR target genetically engineered mice were selected and anesthetized by inhalation. The left ureter was ligated. One day after the UUO surgery, the mice were administered an equimolar ratio of the bispecific antibody I700021 and the corresponding parental monoclonal antibodies 900792 and 700077. After administration, the operated kidney was harvested, and paraffin sections of kidney tissue were prepared using a paraffin sectioning machine. Histochemical staining was performed using PAS staining reagent or Masson-Trichrome reagent. After dehydration and clearing, the sections were mounted and baked overnight in a 60°C oven. Observation and photography were performed using an upright microscope.
[0310] Figure 9 shows the PAS staining quantitative analysis results of the control group and the antibody of the present invention. As shown in Figure 10, the Masson staining quantitative analysis results show that UUO significantly induced fibrosis in the renal tubules and interstitial tissue of mice. Compared with the model group, the intervention regimens of each tested antibody 900792, I700021, and 700077 could significantly inhibit renal tubules and interstitial fibrosis.
[0311] Example 4: The effect of anti-TSLP / IL-11 bispecific antibody on the improvement of atopic dermatitis in an animal model.
[0312] This experiment used MC903 combined with OXA to induce TSLP / TSLPR transgenic mice (purchased from Biocytogen) to establish an atopic dermatitis (AD) model. The efficacy of the anti-TSLP / IL-11 bispecific antibody (I700021) in this model was verified, with equimolar amounts of anti-TSLP monoclonal antibody (900792) and anti-IL-11 monoclonal antibody (700077) used as controls.
[0313] The backs of the experimental mice were shaved, and they were randomly divided into groups according to body weight. The mice were induced to develop the MC903+OXA model. During the modeling period (Day 0-21), 30 μM MC903 was applied every morning, and 0.1% OXA was applied every three days in the afternoon, with a four-hour interval between the two treatments on the same day. The test drug was administered intraperitoneally starting at Day 0. The model skin and other components were analyzed at the experimental endpoint.
[0314] The experimental results are shown in Figures 11-12. Antibodies 900792, I700021, and 700077 can all effectively reduce the expression of the skin Th2 inflammatory factor IL-4 and effectively reduce the number of eosinophils. The efficacy of the TSLP / IL-11 bispecific antibody is better than that of the two monoclonal antibodies.
Claims
1. Use of an antibody and / or antigen binding fragment for the treatment of inflammation and / or fibrosis, characterized in that, The antibody and / or antigen-binding fragment includes a first binding domain capable of targeting IL-11 and a second binding domain capable of targeting TSLP.
2. Use according to claim 1, characterized in that, The first binding domain in the antibody and / or antigen binding fragment capable of targeting IL-11 includes HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO:
4.
3. Use according to claim 1 or 2, characterized in that, The first binding domain capable of targeting IL-11 comprises HCDR3, HCDR2, and HCDR1 of the heavy chain variable region VH; wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO:1, the amino acid sequence of HCDR2 is shown in SEQ ID NO:2, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:
3.
4. Use according to any one of claims 1 to 3, characterized in that, The first binding domain capable of targeting IL-11 includes the antibody heavy chain variable region VH, and the VH contains the amino acid sequence shown in SEQ ID NO:
4.
5. Use according to any one of claims 1 to 4, characterized in that, The first binding domain that can target IL-11 is VHH.
6. Use according to any one of claims 1 to 5, characterized in that, The VHH comprises the amino acid sequence shown in SEQ ID NO:4 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% compared to it.
7. Use according to any one of claims 1 to 6, characterized in that, The antigen-binding fragments are selected from the following group: Fab, Fab', F(ab)2, Fv fragment, F(ab')2, scFv, di-scFv, VHH and dAb fragment.
8. Use according to any one of claims 1 to 7, characterized in that, The antibody and / or antigen-binding fragment capable of targeting the second binding domain of TSLP includes HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO:
14.
9. Use according to any one of claims 1 to 8, characterized in that, The antibody and / or antigen-binding fragment capable of targeting the second binding domain of TSLP includes LCDR1, LCDR2, and LCDR3 of VL as shown in SEQ ID NO:
15.
10. Use according to any one of claims 1 to 9, characterized in that, The second binding domain capable of targeting TSLP comprises HCDR1, HCDR2, and HCDR3 of the heavy chain variable region VH; wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO:8, the amino acid sequence of HCDR2 is shown in SEQ ID NO:9, and the amino acid sequence of HCDR3 is shown in SEQ ID NO:
10.
11. Use according to any one of claims 1 to 10, characterized in that, The second binding domain capable of targeting TSLP comprises LCDR1, LCDR2, and LCDR3 of the light chain variable region VL; wherein the amino acid sequence of LCDR1 is shown in SEQ ID NO:11, the amino acid sequence of LCDR2 is shown in SEQ ID NO:12, and the amino acid sequence of LCDR3 is shown in SEQ ID NO:
13.
12. Use according to any one of claims 1 to 11, characterized in that, The second binding domain capable of targeting TSLP comprises an antibody heavy chain variable region VH as shown in SEQ ID NO:14 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to it.
13. Use according to any one of claims 1 to 12, characterized in that, The second binding domain capable of targeting TSLP comprises an antibody light chain variable region VL as shown in SEQ ID NO:15 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to it.
14. Use according to any one of claims 1 to 13, characterized in that, The second binding domain capable of targeting TSLP comprises a combination of VH and VL as shown in SEQ ID NO:14 and 15 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to them.
15. Use according to any one of claims 1 to 14, characterized in that, The second binding domain capable of targeting TSLP includes the antibody heavy chain constant region.
16. Use according to claim 15, characterized in that, The antibody heavy chain constant region is derived from the human IgG heavy chain constant region.
17. Use according to any one of claims 1 to 16, characterized in that The second binding domain capable of targeting TSLP includes the constant region of the antibody light chain.
18. Use according to claim 17, characterized in that, The antibody light chain constant region is derived from the human Igκ constant region.
19. Use according to any one of claims 1 to 18, characterized in that The second binding domain capable of targeting TSLP comprises an antibody heavy chain, the antibody heavy chain comprising an amino acid sequence shown in SEQ ID NO:6 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to it.
20. Use according to any one of claims 1 to 19, characterized in that, The second binding domain capable of targeting TSLP comprises an antibody light chain, the antibody light chain comprising an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identical to that shown in SEQ ID NO:
7.
21. Use according to any one of claims 1 to 20, characterized in that, The first binding domain that can target IL-11 and the second binding domain that can target TSLP are directly or indirectly connected.
22. The use according to any one of claims 1 to 21, characterized in that, The C-terminus of the first binding domain that can target IL-11 is connected to the N-terminus of the second binding domain that targets TSLP.
23. Use according to claim 22, characterized in that, The C-terminus of the first binding domain that can target IL-11 is connected to the N-terminus of the heavy chain variable region VH that targets the second binding domain of TSLP.
24. Use according to any one of claims 1 to 21, characterized in that, The N-terminus of the first binding domain that can target IL-11 is connected to the C-terminus of the second binding domain that targets TSLP.
25. Use according to claim 24, characterized in that, The N-terminus of the first binding domain that can target IL-11 is connected to the C-terminus of the heavy chain constant region that targets the second binding domain of TSLP.
26. The use according to any one of claims 1 to 25, characterized in that, The first binding domain that can target IL-11 is connected to the second binding domain that targets TSLP via a connector.
27. Use according to claim 26, characterized in that, The linker includes a peptide linker.
28. Use according to claim 26 or 27, characterized in that, The linker contains an amino acid sequence of (GGGGS)n, where n is any positive integer from 0 to 10.
29. Use according to any one of claims 26-28, characterized in that, The linker contains the amino acid sequence shown in GGGGSGGGGS (SEQ ID NO:5).
30. The use according to any one of claims 1 to 29, characterized in that, The multispecific molecule contains two first binding domains capable of targeting IL-11.
31. Use according to claim 30, characterized in that, The two first binding domains that can target IL-11 are directly or indirectly connected to the N-terminus of the two heavy chains that target the second binding domain of TSLP.
32. The use according to claim 30, characterized in that, The two first binding domains that can target IL-11 are directly or indirectly connected to the C-terminus of the two heavy chains that target the second binding domain of TSLP.
33. The use according to any one of claims 1 to 32, characterized in that, The multispecific molecule comprises a first polypeptide chain and a second polypeptide chain.
34. Use according to claim 33, characterized in that, The first polypeptide chain comprises a heavy chain that can target a first binding domain of IL-11 and a second binding domain of TSLP.
35. Use according to claim 34, characterized in that, The first polypeptide chain contains a heavy chain whose N-terminus is directly or indirectly linked to a first binding domain capable of targeting IL-11 and a second binding domain capable of targeting TSLP.
36. The use according to claim 34, characterized in that The first polypeptide chain contains a heavy chain whose C-terminus is directly or indirectly linked to a first binding domain capable of targeting IL-11 and a second binding domain capable of targeting TSLP.
37. Use according to any one of claims 33-36, characterized in that, The first polypeptide chain contains a heavy chain comprising a first binding domain capable of targeting IL-11 and a second binding domain capable of targeting TSLP, which are linked together by a linker.
38. The use according to any one of claims 33 to 37, characterized in that The first polypeptide chain contains the amino acid sequence shown in SEQ ID NO:
18.
39. Use according to any one of claims 33-38, characterized in that, The second polypeptide chain comprises a light chain containing the second binding domain.
40. Use according to any one of claims 33-39, characterized in that, The second polypeptide chain contains the amino acid sequence shown in SEQ ID NO:
19.
41. The use according to any one of claims 33 to 40, characterized in that, The multispecific molecule comprises two first polypeptide chains and two second polypeptide chains.
42. The use according to claim 41, characterized in that The first polypeptide chain and the second polypeptide chain are linked by disulfide bonds.
43. The use according to any one of claims 1 to 42, characterized in that, The inflammatory diseases mentioned include type 2 inflammatory diseases.
44. The use of any of claims 1-43, wherein, The inflammatory disease mentioned can be a disease related to Th2 cells.
45. The use according to any of claims 1 to 44, characterized in that The inflammatory diseases mentioned can be asthma, atopic dermatitis, etc.
46. The use according to any one of claims 1 to 42, characterized in that, The fibrosis is fibrosis of the heart, liver, kidneys, lungs, skin, or eyes.
47. The use according to any one of claim 46, characterized in that, The fibrosis is present in the lungs.
48. The use according to claim 47, characterized in that The fibrosis is pulmonary fibrosis.
49. The use according to claim 48, characterized in that The pulmonary fibrosis mentioned can be asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, etc.
50. The use of claim 46, wherein, The fibrosis is present in the kidneys.
51. The use according to claim 50, characterized in that The fibrosis is renal fibrosis.
52. The use of claim 46, wherein, The fibrosis is present in the skin.
53. The use according to claim 52, characterized in that The skin fibrosis mentioned can be atopic dermatitis, etc.
54. Use of a drug combination comprising a first antibody capable of targeting IL-11 and a second antibody targeting TSLP in the treatment of inflammation and / or fibrosis.
55. The use according to claim 54, characterized in that The first antibody and the second antibody exist in the form of a mixture.
56. Use according to claim 54 or 55, characterized in that, The first antibody and the second antibody exist independently.
57. The use according to any one of claims 54-56, characterized in that The antibodies are selected from the following group: monoclonal antibodies, single-chain antibodies, chimeric antibodies, nanobodies, multispecific antibodies, humanized antibodies, and fully human antibodies.
58. The use according to any one of claims 54-57, characterized in that, The first antibody comprises HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO:
4.
59. The use according to any one of claims 54-58, characterized in that, The first antibody comprises HCDR3, HCDR2 and HCDR1 of the heavy chain variable region VH; wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO:1, the amino acid sequence of HCDR2 is shown in SEQ ID NO:2 and the amino acid sequence of HCDR3 is shown in SEQ ID NO:
3.
60. The use according to any one of claims 54-59, characterized in that, The first antibody contains a variable region VH in the antibody heavy chain, and the amino acid sequence of the VH is shown in SEQ ID NO:
4.
61. The use according to any one of claims 54-60, characterized in that, The first antibody is a nanobody that contains the amino acid sequence shown in SEQ ID NO:4 and / or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% compared to it.
62. The use according to any one of claims 54-61, characterized in that The second antibody comprises HCDR1, HCDR2 and HCDR3 of VH as shown in SEQ ID NO:
14.
63. The use according to any one of claims 54-62, characterized in that, The second antibody comprises LCDR1, LCDR2 and LCDR3 of VL as shown in SEQ ID NO:
15.
64. The use according to any one of claims 54-63, characterized in that The second antibody comprises HCDR1, HCDR2 and HCDR3 of the heavy chain variable region VH; wherein the amino acid sequence of HCDR1 is shown in SEQ ID NO:8, the amino acid sequence of HCDR2 is shown in SEQ ID NO:9 and the amino acid sequence of HCDR3 is shown in SEQ ID NO:
10.
65. The use according to any one of claims 54 to 64, characterized in that, The second antibody comprises LCDR1, LCDR2 and LCDR3 of light chain variable region VL; wherein the amino acid sequence of LCDR1 is shown in SEQ ID NO:11, the amino acid sequence of LCDR2 is shown in SEQ ID NO:12 and the amino acid sequence of LCDR3 is shown in SEQ ID NO:
13.
66. The use according to any one of claims 54-65, characterized in that The second antibody comprises an antibody heavy chain variable region VH as shown in SEQ ID NO:14 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to it.
67. The use of any of claims 54-66, wherein, The second antibody comprises an antibody light chain variable region VL as shown in SEQ ID NO:15 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity compared to it.
68. The use of any of claims 54-67, wherein, The second antibody comprises a combination of VH and VL as shown in SEQ ID NO:14 and 15 and / or having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity compared to them.
69. The use of any of claims 54-68, wherein, The second antibody comprises an antibody heavy chain, which comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identical to that shown in SEQ ID NO:
6.
70. The use of any of claims 54-69, wherein, The second antibody comprises an antibody light chain, the antibody light chain comprising an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identical to that shown in SEQ ID NO:
7.
71. The use of any of claims 54-70, wherein, The inflammatory diseases mentioned include type 2 inflammatory diseases.
72. The use of any of claims 54-71, wherein, The inflammatory disease mentioned can be a disease related to Th2 cells.
73. Use according to claims 54-72, characterized in that, The inflammatory diseases mentioned can be asthma, atopic dermatitis, etc.
74. The use according to any one of claims 54-70, characterized in that The fibrosis is fibrosis of the heart, liver, kidneys, lungs, skin, or eyes.
75. The use according to claim 74, characterized in that The fibrosis is present in the lungs.
76. The use according to claim 75, characterized in that The fibrosis is pulmonary fibrosis.
77. The use according to claim 76, characterized in that The pulmonary fibrosis mentioned can be asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, etc.
78. The use of claim 74, wherein, The fibrosis is present in the kidneys.
79. The use according to claim 78, characterized in that The fibrosis is renal fibrosis.
80. The use of claim 74, wherein, The fibrosis is present in the skin.
81. The use according to claim 80, characterized in that The skin fibrosis mentioned can be atopic dermatitis, etc.
82. Use of one or more nucleic acid molecules encoding an antibody and / or antigen-binding fragment according to any one of claims 1-53 in the treatment of inflammation and / or fibrosis.
83. Use of a carrier comprising the nucleic acid molecule according to claim 82 in the treatment of inflammation and / or fibrosis.
84. Use of a cell comprising a nucleic acid molecule according to claim 82 or a carrier according to claim 83 in the treatment of inflammation and / or fibrosis.
85. Use of a chimeric antigen receptor comprising an antibody and / or antigen-binding fragment according to any one of claims 1-53 in the treatment of inflammation and / or fibrosis.
86. Use of an immunoconjugate comprising an antibody and / or antigen-binding fragment according to any one of claims 1-53 in the treatment of inflammation and / or fibrosis.
87. The antibody and / or antigen-binding fragment according to any one of claims 1-53, the drug combination according to any one of claims 54-81, the nucleic acid molecule according to claim 82, the carrier according to claim 83, the cell according to claim 84, the chimeric antigen receptor according to claim 85, and / or the immunoconjugate according to claim 86 for the prevention, relief, and treatment of inflammatory and / or fibrotic diseases and / or conditions.
88. The use according to claim 87, wherein the inflammatory disease comprises type 2 inflammatory disease.
89. The use according to any one of claims 87 or 88, wherein the inflammatory disease may be a Th2 cell-related disease.
90. The use according to any one of claims 87-89, wherein the inflammatory disease may be asthma, atopic dermatitis, etc.
91. The use according to claim 87, wherein the fibrosis is fibrosis of the heart, liver, kidneys, lungs, skin or eyes.
92. The use according to claim 91, wherein the fibrosis is present in the lungs.
93. The use according to claim 92, wherein the fibrosis is pulmonary fibrosis.
94. In the use according to claim 93, the pulmonary fibrosis may be asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, etc.
95. The use according to claim 91, wherein the fibrosis is present in the kidney.
96. The use according to claim 95, wherein the fibrosis is renal fibrosis.
97. The use according to claim 91, wherein the fibrosis is present in the skin.
98. In the use according to claim 97, the skin fibrosis may be atopic dermatitis, etc.
99. Use in the preparation of a medicament for the preparation of an antibody and / or antigen-binding fragment according to any one of claims 1-53, a pharmaceutical combination according to any one of claims 54-81, a nucleic acid molecule according to claim 82, a carrier according to claim 83, a cell according to claim 84, a chimeric antigen receptor according to claim 85, and / or an immunoconjugate according to claim 86, wherein the medicament is used for the prevention, relief, and / or treatment of inflammatory and / or fibrotic diseases and / or conditions.
100. The use according to claim 99, wherein the inflammatory disease comprises type 2 inflammatory disease.
101. The use according to claim 99 or 100, wherein the inflammatory disease may be a Th2 cell-related disease.
102. The use according to any one of claims 99-101, wherein the inflammatory disease may be asthma, atopic dermatitis, etc.
103. The use according to claim 99, wherein the fibrosis is fibrosis of the heart, liver, kidneys, lungs, skin or eyes.
104. The use according to claim 103, wherein the fibrosis is present in the lungs.
105. The use according to claim 104, wherein the fibrosis is pulmonary fibrosis.
106. The use according to claim 105, wherein the pulmonary fibrosis can be asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, etc.
107. The use according to claim 103, wherein the fibrosis is present in the kidney.
108. The use according to claim 107, wherein the fibrosis is renal fibrosis.
109. The use according to claim 103, wherein the fibrosis is present in the skin.
110. The use according to claim 109, wherein the skin fibrosis may be atopic dermatitis, etc.
111. The antibody and / or antigen-binding fragment according to any one of claims 1-53, the pharmaceutical combination according to any one of claims 54-81, the nucleic acid molecule according to claim 82, the carrier according to claim 83, the cell according to claim 84, the chimeric antigen receptor according to claim 85, and / or the immunoconjugate according to claim 86 for the prevention and / or treatment of inflammatory and / or fibrotic diseases and / or conditions.
112. The use according to any one of claims 111, wherein the inflammatory disease comprises type 2 inflammatory disease.
113. The use according to claim 111 or 112, wherein the inflammatory disease may be a Th2 cell-related disease.
114. The use according to any one of claims 111-113, wherein the inflammatory disease may be asthma, atopic dermatitis, etc.
115. The use according to claim 111, wherein the fibrosis is fibrosis of the heart, liver, kidneys, lungs, skin or eyes.
116. The use according to claim 115, wherein the fibrosis is present in the lungs.
117. The use according to claim 116, wherein the fibrosis is pulmonary fibrosis.
118. The use according to claim 117, wherein the pulmonary fibrosis can be asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, and the like.
119. The use according to claim 115, wherein the fibrosis is present in the kidney.
120. The use according to claim 119, wherein the fibrosis is kidney fibrosis.
121. The use according to claim 115, wherein the fibrosis is present in the skin.
122. The use according to claim 121, wherein the skin fibrosis can be atopic dermatitis and the like.
